43 results on '"Cairo, Mitchell S."'
Search Results
2. Contributors
- Author
-
Abman, Steven H., primary, Ahmed, Amina, additional, Allen, Marilee C., additional, Askenazi, David, additional, Back, Stephen A., additional, Baldwin, H. Scott, additional, Ballard, Roberta A., additional, Bancalari, Eduardo, additional, Bates, Carlton M., additional, Batisky, Donald L., additional, Baumgart, Stephen, additional, Benedetti, Thomas J., additional, Berry, Gerard T., additional, Bianchi, Diana W., additional, Binenbaum, Gil, additional, Bollepalli, Sureka, additional, Bonifacio, Sonia L., additional, Cairo, Mitchell S., additional, Campbell, Katherine H., additional, Caplan, Michael, additional, Cederbaum, Stephen, additional, Chandra, Sudhish, additional, Chen, Ming, additional, Claure, Nelson, additional, Clyman, Ronald I., additional, Cohen, Bernard A., additional, Cole, F. Sessions, additional, Copelovitch, Lawrence, additional, Cunningham, Michael, additional, de Alba Campomanes, Alejandra G., additional, Dees, Ellen, additional, Denne, Scott C., additional, Devaskar, Sherin U., additional, DiBlasi, Robert M., additional, Dimmitt, Reed A., additional, Eichenwald, Eric C., additional, Eisenstein, Eli M., additional, Evans, Jacquelyn R., additional, Evans, Kelly, additional, Farmer, Diana L., additional, Ferrieri, Patricia, additional, Ferriero, Donna M., additional, Finer, Neil N., additional, Fraga, Maria Victoria, additional, Furman, Lydia, additional, Furth, Susan, additional, Gauda, Estelle B., additional, Glader, Bertil, additional, Gleason, Christine A., additional, Goldberg, Michael J., additional, Gonzalez, Fernando, additional, Gopalani, Sameer, additional, Grant, P. Ellen, additional, Greene, Carol L., additional, Guevara-Gallardo, Salvador, additional, Guignard, Jean-Pierre, additional, Guttentag, Susan, additional, Haldeman-Englert, Chad R., additional, Hansen, Thomas, additional, Hing, Anne V., additional, Hohimer, A. Roger, additional, Hostetter, Margaret K., additional, Hull, Andrew D., additional, Jackson, J. Craig, additional, Jain, Lucky, additional, Jain, Vandana, additional, Janjua, Halima Saadia, additional, Juul, Sandra E., additional, Kalkunte, Satyan, additional, Kaplan, Bernard S., additional, Keller, Roberta L., additional, Kelly, Thomas F., additional, Kern, Steven E., additional, Kerkar, Nanda, additional, Kinsella, John P., additional, Kirsch, Roxanne, additional, Kleinman, Monica E., additional, Klitzner, Thomas S., additional, Lambert, Sarah M., additional, Lantos, John D., additional, Leone, Tina A., additional, Leppert, Mary, additional, Levy, Harvey L., additional, Lewin, Mark, additional, Lin-Su, Karen, additional, L. Loh, Mignon, additional, Lorch, Scott A., additional, Lugo, Ralph A., additional, Mai, Volker, additional, Marino, Bradley S., additional, Markovitz, Barry, additional, Marquard, Kerri, additional, Martin, Camilia R., additional, Martin, Richard J., additional, Matthay, Katherine K., additional, Matthews, Dana C., additional, Mayock, Dennis E., additional, Meadow, William L., additional, Menon, Ram K., additional, Mercuri, Eugenio, additional, Mohan, Sowmya S., additional, Moley, Kelle, additional, Mollen, Thomas J., additional, Moore, Jeremy P., additional, Moore, Thomas R., additional, Munson, David A., additional, Murray, Jeffrey C., additional, Neu, Josef, additional, New, Maria I., additional, Nguyen-Vermillion, Annie, additional, Niklas, Victoria, additional, Nimkarn, Saroj, additional, Padbury, James F., additional, Pane, Marika, additional, Paneth, Nigel, additional, Parker, Thomas A., additional, Patterson, Janna C., additional, Pettker, Christian M., additional, Plawner, Lauren L., additional, Poenaru, Dan, additional, Poindexter, Brenda B., additional, Posencheg, Michael A., additional, Prabhu, Sanjay P., additional, Püttgen, Katherine B., additional, Quinn, Graham E., additional, Raju, Tonse N.K., additional, Ramos, Gladys A., additional, Reinking, Benjamin E., additional, Richardson, C. Peter, additional, Rimoin, David L., additional, Robbins, Elizabeth, additional, Robertson, Richard L., additional, Rollins, Mark D., additional, Rose, Susan R., additional, Rosen, Mark A., additional, Rubin, Lewis P., additional, Sahai, Inderneel, additional, Saitta, Sulagna C., additional, Sánchez, Pablo J., additional, Satou, Gary M., additional, Schanler, Richard J., additional, Scher, Mark S., additional, Schleiss, Mark R., additional, Scholz, Thomas D., additional, Schwaderer, Andrew L., additional, Seri, Istvan, additional, Sharma, Surendra, additional, Shereck, Evan B., additional, Sibley, Eric, additional, Signore, Caroline, additional, Simmons, Rebecca, additional, Smith, Jeffrey B., additional, Smith, Lorie B., additional, Song, Clara, additional, Steinhorn, Robin H., additional, Suchy, Frederick J., additional, Sulyok, Endre, additional, Tarczy-Hornoch, Peter, additional, Taylor, George A., additional, Taylor, James A., additional, Thomas, Janet A., additional, Tiller, George E., additional, Tran, Mark M., additional, Trautman, Michael Stone, additional, Upperman, Jeffrey S., additional, van de Ven, Carmella, additional, Vernon, Margaret M., additional, Allan Walker, W., additional, Wallen, Linda D., additional, Waller, Sarah A., additional, Warady, Bradley A., additional, Ward, Robert M., additional, Watchko, Jon F., additional, Wernovsky, Gil, additional, White, Klane K., additional, Williams, Calvin B., additional, Woodrum, David, additional, Woodward, George A., additional, Wright, Dakara Rucker, additional, Wright, Jeffrey A., additional, Wright, Linda L., additional, Young, Christopher M., additional, Young, Guy, additional, Zackai, Elaine H., additional, and Zderic, Stephen A., additional
- Published
- 2012
- Full Text
- View/download PDF
3. Contributors
- Author
-
Abramson, Jon S., primary, Abzug, Mark J., additional, Aiken, John J., additional, A-kader, H. Hesham, additional, Akdis, Cezmi A., additional, Alderman, Harold, additional, Alemzadeh, Ramin, additional, Alessandrini, Evaline A., additional, Ali, Omar, additional, Ambalavanan, Namasivayam, additional, Anderson, Karl E., additional, Anderson, Peter M., additional, Anthony, Kelly K., additional, Antoon, Alia Y., additional, Ardoin, Stacy P., additional, Arndt, Carola A.S., additional, Arnon, Stephen S., additional, Aronoff, Stephen C., additional, Asher, David M., additional, Asselin, Barbara L., additional, Ater, Joann L., additional, Atkins, Dan, additional, Augustine, Erika F., additional, Augustyn, Marilyn, additional, Avner, Ellis D., additional, Azimi, Parvin H., additional, Bacino, Carlos A., additional, Baldassano, Robert N., additional, Bales, Christina, additional, Balistreri, William F., additional, Baltimore, Robert S., additional, Balwani, Manisha, additional, Baqar, Shahida, additional, Barron, Christine E., additional, Bass, Dorsey M., additional, Batshaw, Mark L., additional, Behrman, Richard E., additional, Bell, Michael J., additional, Belmont, John W., additional, Benjamin, Daniel K., additional, Bennett, Michael J., additional, Bernstein, Daniel, additional, Bhatia, Jatinder, additional, Bhutta, Zulfiqar Ahmed, additional, Biesecker, Leslie G., additional, Birmingham, James, additional, Blanchard, Samra S., additional, Blanton, Ronald, additional, Bleyer, Archie, additional, Boamah, C.D.R. Lynelle M., additional, Boas, Steven R., additional, Boat, Thomas F., additional, Bockting, Walter, additional, Boguniewicz, Mark, additional, Bonthius, Daniel J., additional, Boxer, Laurence A., additional, Brandow, Amanda M., additional, Branski, David, additional, Breault, David T., additional, Buckley, Rebecca H., additional, Budek, Cynthia Etzler, additional, Buescher, E. Stephen, additional, Burstein, Gale R., additional, Bustinduy, Amaya Lopez, additional, Cairo, Mitchell S., additional, Camitta, Bruce M., additional, Campbell, Angela Jean Peck, additional, Carey, Rebecca G., additional, Carlo, Waldemar A., additional, Carrigan, Robert B., additional, Caserta, Mary T., additional, Chadwick, Ellen Gould, additional, Chamberlain, Lisa J., additional, Chapman, Jennifer I., additional, Cheifetz, Ira M., additional, Chemaitilly, Wassim, additional, Chen, Sharon F., additional, Chen, Yuan-Tsong, additional, Chesney, Russell W., additional, Chiriboga, Jennifer A., additional, Christensen, Robert D., additional, Chu, Andrew, additional, Chusid, Michael J., additional, Cieslak, Theodore J., additional, Clark, Jeff A., additional, Cleary, Thomas G., additional, Clemens, John David, additional, Cohen, Joanna S., additional, Cohen, Mitchell B., additional, Cohen, Pinchas, additional, Cohen-Wolkowiez, Michael, additional, Colbert, Robert A., additional, Cole, F. Sessions, additional, Cole, Joanna C.M., additional, Colombo, John L., additional, Cooper, Amber R., additional, Covar, Ronina A., additional, Cromer, Barbara, additional, Crowe, James E., additional, Cunningham, Natoshia Raishevich, additional, Czinn, Steven J., additional, Darville, Toni, additional, Daum, Robert S., additional, Davidson, Richard S., additional, Davies, H. Dele, additional, Dayan, Peter S., additional, DeBaun, Michael R., additional, Degaffe, Guenet H., additional, DeMaso, David R., additional, Denison, Mark R., additional, Dent, Arlene E., additional, DeSilva, Nirupama K., additional, Desnick, Robert J., additional, deVeber, Gabrielle, additional, DeWitt, Esi Morgan, additional, Dhamne, Chetan Anil, additional, Dhawan, Anil, additional, Dietz, Harry, additional, Donoghue, Lydia J., additional, Donohoue, Patricia A., additional, Donovan, Mary K., additional, Dormans, John P., additional, Doyle, Daniel A., additional, Doyle, Jefferson, additional, Dreskin, Stephen C., additional, Drummond, Denis S., additional, Dubowitz, Howard, additional, Dumler, J. Stephen, additional, Duncan, Janet, additional, Duncan, Paula M., additional, Dyner, LauraLe, additional, Earing, Michael G., additional, Edgerton, Elizabeth A., additional, Egan, Marie, additional, Elder, Jack S., additional, Eleoff, Sara B., additional, Elfenbein, Dianne S., additional, Eppes, Stephen C., additional, Ewald, Michele Burns, additional, Fairley, Jessica K., additional, Feigelman, Susan, additional, Felice, Marianne E., additional, Felner, Eric I., additional, Fels, Edward, additional, Ferkol, Thomas, additional, Finder, Jonathan D., additional, Fiorino, Kristin N., additional, Fleece, David M., additional, Flynn, Patricia M., additional, Forman, Joel A., additional, Frank, Michael M., additional, Freedman, Melvin H., additional, Frei-Jones, Melissa, additional, Friedman, Jared E., additional, Gahagan, Sheila, additional, Gardiner, Paula, additional, Garibaldi, Luigi, additional, Gauthier, Gregory M., additional, Gedalia, Abraham, additional, Gelmini, Matthew J., additional, Gerber, Michael A., additional, Gibson, K. Michael, additional, Gibson, Mark, additional, Gigliotti, Francis, additional, Gilliam, Walter S., additional, Gilsdorf, Janet R., additional, Ginsburg, Charles M., additional, Glascoe, Frances P., additional, Goldmann, Donald A., additional, Goodman, Denise M., additional, Gorelick, Marc H., additional, Gosselin, Gary J., additional, Gould, Jane M., additional, Goulet, Olivier, additional, Granoff, Dan M., additional, Green, Michael, additional, Green, Thomas P., additional, Greenbaum, Larry A., additional, Grino, Marie Michelle, additional, Grossman, Andrew B., additional, Grossman, David C., additional, Guarino, Alfredo, additional, Hackney, Lisa R., additional, Haddad, Gabriel G., additional, Haddad, Joseph, additional, Hagan, Joseph F., additional, Halstead, Scott B., additional, Hammerschlag, Margaret R., additional, Hamvas, Aaron, additional, Harris, James C., additional, Hartman, Mary E., additional, Haslam, David B., additional, Hauck, Fern R., additional, Hayden, Gregory F., additional, Hecht, Jacqueline T., additional, Heidemann, Sabrina M., additional, Hendley, J. Owen, additional, Henretig, Fred M., additional, Heresi, Gloria P., additional, Hershey, Andrew D., additional, Herzog, Cynthia E., additional, Hochberg, Jessica, additional, Holinger, Lauren D., additional, Hord, Jeffrey D., additional, Horn, B. David, additional, Horton, William A., additional, Hosalkar, Harish S., additional, Hosono, Hidekazu, additional, Hotez, Peter J., additional, Howenstine, Michelle S., additional, Huddleston, Heather G., additional, Huff, Vicki, additional, Hug, Denise, additional, Huh, Winston W., additional, Hunt, Carl E., additional, Hunter, Anna Klaudia, additional, Ibeziako, Patricia, additional, Jacobs, Richard F., additional, Jensen, Peter, additional, Jenson, Hal B., additional, John, Chandy C., additional, Johnston, Michael V., additional, Johnston, Richard B., additional, Jones, Bridgette L., additional, Jones, James F., additional, Joselow, Marsha, additional, Kalaskar, Anupama, additional, Kaljee, Linda, additional, Kamat, Deepak, additional, Kansra, Alvina R., additional, Kaplan, Sheldon L., additional, Katz, Emily R., additional, Kazura, James W., additional, Keane, Virginia, additional, Kearns, Gregory L., additional, Kelly, Desmond P., additional, Kelsen, Judith, additional, Kemper, Kathi J., additional, Kennedy, Melissa, additional, Kerem, Eitan, additional, Kerschner, Joseph E., additional, Khan, Seema, additional, Kim, Young-Jee, additional, King, Charles H., additional, Kinsman, Stephen L., additional, Kirton, Adam, additional, Kishnani, Priya S., additional, Kizer, Nora T., additional, Kleiman, Martin B., additional, Klein, Bruce L., additional, Klein, Bruce S., additional, Klein, Michael D., additional, Kliegman, Robert M., additional, Koch, William C., additional, Kochanek, Patrick M., additional, Kodish, Eric, additional, Kohlhoff, Stephan A., additional, Krane, Elliot J., additional, Krause, Peter J., additional, Kreipe, Richard E., additional, Krug, Steven E., additional, Kuttesch, John F., additional, Kwon, Jennifer M., additional, Lachenauer, Catherine S., additional, Ladisch, Stephan, additional, LaFranchi, Stephen, additional, Lakser, Oren, additional, Lande, Marc B., additional, Landrigan, Philip J., additional, Landry, Gregory L., additional, Lane, Wendy G., additional, LaRussa, Philip S., additional, Lee, Brendan, additional, Lee, Chul, additional, Lee, K. Jane, additional, Leeder, J. Steven, additional, Lehman, Rebecca K., additional, Lentze, Michael J., additional, Lerner, Norma B., additional, Lestrud, Steven, additional, Leung, Donald Y.M., additional, Liacouras, Chris A., additional, Liewer, Susanne, additional, Liu, Andrew H., additional, Lo, Stanley F., additional, Locatelli, Franco, additional, Long, Sarah S., additional, Lopez, Anna Lena, additional, Lossef, Steven V., additional, Lowry, Jennifer A., additional, Lucco, Kerith, additional, Lyon, G. Reid, additional, Mahajan, Prashant V., additional, Maheshwari, Akhil, additional, Majzoub, Joseph A., additional, Maqbool, Asim, additional, Maranich, Ashley M., additional, Marin, Mona, additional, Marini, Joan C., additional, Markowitz, Morri, additional, Marks, Kevin P., additional, Maroushek, Stacene R., additional, Mason, Wilbert H., additional, Mastropietro, Christopher, additional, Matalon, Kimberlee M., additional, Matalon, Reuben K., additional, Mazor, Robert, additional, McColley, Susanna A., additional, McGovern, Margaret M., additional, McLean, Heather S., additional, McLeod, Rima, additional, Melby, Peter C., additional, Melvin, Joseph John, additional, Merritt, Diane F., additional, Mezoff, Ethan A., additional, Michaels, Marian G., additional, Miethke, Alexander G., additional, Mikati, Mohamad A., additional, Milgrom, Henry, additional, Miller, E. Kathryn, additional, Mink, Jonathan W., additional, Mitchell, Grant A., additional, Montgomery, Robert R., additional, Morelli, Joseph G., additional, Moscicki, Anna-Barbara, additional, Moser, Hugo W., additional, Moyer, Kathryn D., additional, Murphy, James R., additional, Murphy, Timothy F., additional, Murray, Thomas S., additional, Natale, Mindo J., additional, Neal, William A., additional, Ness, Jayne, additional, Neville, Kathleen A., additional, Nevin, Mary A., additional, Newburger, Jane W., additional, Newburger, Peter E., additional, Nield, Linda S., additional, Noah, Zehava, additional, Nogee, Lawrence M., additional, Norris, Robert L., additional, Obaro, Stephen K., additional, Obeid, Makram, additional, Ochoa, Theresa J., additional, O'Donnell, Katherine A., additional, Ohls, Robin K., additional, Okwo-Bele, Jean-Marie, additional, Oldham, Keith T., additional, Olitsky, Scott E., additional, Olsson, John, additional, Orenstein, Susan R., additional, Orenstein, Walter A., additional, Owens, Judith A., additional, Packman, Charles H., additional, Painter, Michael J., additional, Pais, Priya, additional, Pan, Cynthia G., additional, Pannikar, Vijay, additional, Pappas, Diane E., additional, Parish, Anjali, additional, Parks, John S., additional, Parks, Laura A., additional, Patterson, Maria Jevitz, additional, Patwari, Pallavi P., additional, Peters, Timothy R., additional, Pickering, Larry K., additional, Pless, Misha L., additional, Plummer, Laura S., additional, Porter, Craig C., additional, Powell, Dwight A., additional, Price, David T., additional, Prober, Charles G., additional, Quan, Linda, additional, Quint, Elisabeth H., additional, Rabinovich, C. Egla, additional, Raffini, Leslie J., additional, Ramirez-Montealegre, Denia, additional, Raviola, Giuseppe, additional, Reed, Ann M., additional, Rekate, Harold L., additional, Reller, Megan E., additional, Remafedi, Gary, additional, Reyes, Jorge D., additional, Rezvani, Geoffrey, additional, Rezvani, Iraj, additional, Ritchey, A. Kim, additional, Rivara, Frederick P., additional, Robinson, Angela Byun, additional, Rogg, Luise E., additional, Roosevelt, Genie E., additional, Rosenberg, David R., additional, Rosenberg, Melissa Beth, additional, Rosenblatt, David S., additional, Roskind, Cindy Ganis, additional, Rotar, Mary M., additional, Rozenfeld, Ranna A., additional, Rush, Sarah Zieber, additional, Ryan, Colleen A., additional, Sachdev, H.P.S., additional, Sachdeva, Ramesh C., additional, Sahin, Mustafa, additional, Salata, Robert A., additional, Salerno, Denise A., additional, Salvana, Edsel Maurice T., additional, Sampson, Hugh A., additional, Sandora, Thomas J., additional, Sandritter, Tracy, additional, Sankar, Wudbhav N., additional, Sarnaik, Ajit Ashok, additional, Sarnaik, Ashok P., additional, Sarnat, Harvey B., additional, Sarwal, Minnie M., additional, Saunders, Mary, additional, Schanberg, Laura E., additional, Schleiss, Mark R., additional, Schor, Nina F., additional, Schroeder, Bill J., additional, Schum, Robert L., additional, Schutze, Gordon E., additional, Scott, Daryl A., additional, Scott, J. Paul, additional, Sectish, Theodore C., additional, Segel, George B., additional, Sehgal, Kriti, additional, Seidman, Ernest G., additional, Serwint, Janet R., additional, Shah, Dheeraj, additional, Shamir, Raanan, additional, Shapiro, Bruce K., additional, Shaw, Richard J., additional, Shaywitz, Bennett A., additional, Shaywitz, Sally E., additional, Shekar, Meera, additional, Shephard, Elena, additional, Sherman, Philip M., additional, Shneider, Benjamin L., additional, Sicherer, Scott H., additional, Sills, Richard, additional, Simms, Mark D., additional, Simões, Eric A.F., additional, Slovis, Thomas L., additional, Smith, P. Brian, additional, Son, Mary Beth F., additional, Sosinsky, Laura Stout, additional, Spahn, Joseph D., additional, Sperling, Mark A., additional, Spicer, Robert, additional, Spiegel, David A., additional, Spoudeas, Helen, additional, Spranger, Jürgen, additional, Sreedharan, Rajasree, additional, Sreedharan, Raman, additional, Stafford, Shawn J., additional, Stager, Margaret M., additional, Stagno, Sergio, additional, Stallings, Virginia A., additional, Stanberry, Lawrence R., additional, Stanley, Charles A., additional, Stanton, Bonita F., additional, Starke, Jeffrey R., additional, Stass-Isern, Merrill, additional, Stechenberg, Barbara W., additional, Stein, Leonard D., additional, Steinbach, William J., additional, Stettler, Nicolas, additional, Stoll, Barbara J., additional, Storch, Gregory A., additional, Strauss, Ronald G., additional, Suchy, Frederick J., additional, Summar, Karen, additional, Szilagyi, Moira, additional, Tinanoff, Norman, additional, Todd, James K., additional, Tompkins, Lucy S., additional, Tower, Richard L., additional, Troncone, Riccardo, additional, Trott, Amanda A., additional, Tubergen, David G., additional, Turner, David A., additional, Turner, Ronald B., additional, Ullrich, Christina, additional, Van Hare, George F., additional, van Ingen, Jakko, additional, Van Mater, Heather A., additional, van Soolingen, Dick, additional, Van Why, Scott K., additional, Vandana, Pankhuree, additional, Vanderbilt, Douglas, additional, Vanderhoof, Jon A., additional, Velardi, Andrea, additional, Vichinsky, Elliott, additional, Waggoner-Fountain, Linda A., additional, Waguespack, Steven G., additional, Walker, David M., additional, Walter, Heather J., additional, Ware, Stephanie, additional, Watts, Kimberly Danieli, additional, Waxman, Ian M., additional, Weese-Mayer, Debra E., additional, Weise, Kathryn, additional, Weisse, Martin E., additional, Wells, Lawrence, additional, Wen, Jessica, additional, Werlin, Steven L., additional, Wessels, Michael R., additional, Wetmore, Ralph F., additional, Wetzel, Randall C., additional, Wexler, Isaiah D., additional, White, Perrin C., additional, Williams, John V., additional, Willoughby, Rodney E., additional, Wilson, Samantha L., additional, Winnie, Glenna B., additional, Wise, Paul H., additional, Woc-Colburn, Laila, additional, Wolfe, Joanne, additional, Wong, Cynthia J., additional, Worth, Laura L., additional, Wright, Joseph L., additional, Wright, Peter F., additional, Wright, Terry W., additional, Wu, Eveline Y., additional, Wynshaw-Boris, Anthony, additional, Yazigi, Nada, additional, Yogev, Ram, additional, Yudkoff, Marc, additional, Zage, Peter E., additional, Zaidi, Anita K.M., additional, Zeltzer, Lonnie K., additional, Zile, Maija H., additional, Zimmer, Peter, additional, and Zuckerman, Barry, additional
- Published
- 2011
- Full Text
- View/download PDF
4. Lymphoma
- Author
-
Waxman, Ian M., primary, Hochberg, Jessica, additional, and Cairo, Mitchell S., additional
- Published
- 2011
- Full Text
- View/download PDF
5. Neonatal Neutrophil Normal and Abnormal Physiology
- Author
-
Bhatia, Monica, primary, Parravicini, Elvira, additional, van de Ven, Carmella, additional, and Cairo, Mitchell S., additional
- Published
- 2011
- Full Text
- View/download PDF
6. Contributors
- Author
-
Arceci, M.D., Robert J., primary, Acharya, Suchitra S., additional, Alderfer, Melissa A., additional, Atlas, Mark, additional, Bagatell, Rochelle, additional, Bonilla, Mary Ann, additional, Bussel, James, additional, Cairo, Mitchell S., additional, Chen, Andrew, additional, Dome, Jeffrey, additional, DuBois, Steven, additional, Levy, Carolyn Fein, additional, Fish, Jonathan, additional, Friedman, Debra L., additional, Gorlick, Richard, additional, Gratias, Eric, additional, Hochberg, Jessica, additional, Janeway, Katherine A., additional, Kwiatkowski, Janet L., additional, Lanzkowsky, Philip, additional, Lipton, Jeffrey M., additional, Marina, Neyssa, additional, Menell, Jill S., additional, Olson, Thomas A., additional, Prasad, Pinki, additional, Park, Julie R., additional, Prchal, Josef T., additional, Redner, Arlene, additional, Renaud, Thomas, additional, Rheingold, Susan, additional, Rubin, Lorry Glen, additional, Sahdev, Indira, additional, Scerbo, Jessica, additional, Teachey, David T., additional, Issai Vanan, M., additional, Wexler, Leonard H., additional, Wiener, Lori S., additional, and Wolfe, Lawrence, additional
- Published
- 2011
- Full Text
- View/download PDF
7. Contributors
- Author
-
Abbruzzese, James L., primary, Abeloff, Martin D., additional, Abou-Alfa, Ghassan K., additional, Abrahm, Janet L., additional, Abrams, Jeffery S., additional, Acs, Geza, additional, Aisner, Joseph, additional, Aisner, Seena C., additional, Alani, Rhoda M., additional, Alberts, Steven R., additional, Ambinder, Richard F., additional, Andritsos, Leslie A., additional, Appelbaum, Frederick R., additional, Apte, Sachin, additional, Armitage, James O., additional, Armstrong, Deborah, additional, Bagheri, Mamad M., additional, Balch, Charles M., additional, Balducci, Lodovico, additional, Beghé, Claudia, additional, Benjamin, Robert, additional, Bennett, Charles L., additional, Berkowitz, Ross Stuart, additional, Bernstein, Donna, additional, Bishop, Michael R., additional, Blot, William J., additional, Blumgart, Leslie, additional, Bommer, Guido T., additional, Borowitz, Michael J., additional, Brahmer, Julie R., additional, Bramwell, Viven H.C., additional, Brock, Malcom V., additional, Bydon, Ali, additional, Cairo, Mitchell S., additional, Campana, Dario, additional, Carbone, David P., additional, Carter, H. Ballentine, additional, Chadha, Manpreet K., additional, Chan, Daniel W., additional, Chang, Alfred E., additional, Cheung, Nai-Kong V., additional, Christian, Michaele, additional, Clarke, Michael F., additional, Cmelak, Anthony, additional, Coccia, Peter F., additional, Cohen, Alfred M., additional, Coleman, Robert E., additional, Compton, Carolyn, additional, Cooley, Linda D., additional, Cortes, Jorge, additional, Courtneidge, Sara A., additional, Cowan, Kenneth H., additional, Culkin, Daniel J., additional, Dalmau, Josep, additional, D'Angio, Giulio J., additional, Dawson, Laura, additional, Deitcher, Steven R., additional, DeMatteo, Ronald P., additional, DeSimone, Philip A., additional, DeWeese, Theodore L., additional, Digumarthy, Subba R., additional, Dispenzieri, Angela, additional, Dome, Jeffrey S., additional, Donohue, John H., additional, Doroshow, James H., additional, Drebin, Jeffery A., additional, Duda, Dan G., additional, Duffy, Austin, additional, Duska, Linda R., additional, Eisenberger, Mario A., additional, Elstrom, Rebecca L., additional, Erler, Janine T., additional, Ewer, Michael S., additional, Fearon, Eric R., additional, Fecher, Leslie A., additional, Fichera, Alessandro, additional, Filipovich, Alexandra H., additional, Fitzner, Karen A., additional, Foote, Robert L., additional, Foran, James M., additional, Forastiere, Arlene A., additional, Ford, James M., additional, Freifeld, Alison G., additional, Freter, Carl E., additional, Fuller, Arlan F., additional, Furth, Emma E., additional, Garofalo, Michael C., additional, Gebhardt, Mark C., additional, Gerber, N. Lynn, additional, Gharia, Manish, additional, Giaccia, Amato J., additional, Gilbert, Mark R., additional, Glaspy, John, additional, Glover, Katrina Y., additional, Gokaslan, Ziya L., additional, Gökbuget, Nicola, additional, Goldstein, Donald Peter, additional, Gonzalez, Adriana, additional, Goodman, Anne Kathryn, additional, Gordon, Ellen, additional, Green, Daniel M., additional, Grever, Michael R., additional, Grigg, Andrew, additional, Grochow, Louise, additional, Gross, Thomas G., additional, Grossman, Stuart A., additional, Gunderson, Leonard L., additional, Gunkel, Juliet, additional, Gutierrez, Martin, additional, Habermann, Thomas M., additional, Haik, Barrett G., additional, Hainsworth, John D., additional, Hallahan, Dennis, additional, Hanna, Nader N., additional, Harris, Eleanor E.R., additional, Hawk, Ernie, additional, Heideman, Nancy H., additional, Heideman, Richard L., additional, Helman, Lee J., additional, Hochberg, Jessica, additional, Hoelzer, Dieter, additional, Holen, Ingunn, additional, Horning, Sandra J., additional, Huang, Kim, additional, Illei, Peter B., additional, Jaffe, Elaine S., additional, Jagannath, Sanjay B., additional, Jain, Rakesh K., additional, Jarnagin, William, additional, Jhingran, Anuja, additional, Johnson, David H., additional, Jones, Heather, additional, Judy, Kevin D., additional, Juergens, Rosalyn A., additional, Kant, Jeffrey A., additional, Kantarjian, Hagop, additional, Karcioglu, Zeynel A., additional, Karyadi, Danielle M., additional, Kased, Norbert, additional, Kastan, Michael B., additional, Kaul, Daniel R., additional, Kawaoka, John, additional, Kemeny, Margaret, additional, Kemeny, Nancy, additional, Kensler, Thomas W., additional, Kleinberg, Lawrence R., additional, Kobrinsky, Boris, additional, Kowalski, Jeanne, additional, Kummar, Shivaani, additional, Lal, Geeta, additional, Lambert, Paul F., additional, Lange, Julie R., additional, Laskin, Janessa, additional, Lee, Fred, additional, Lee, Susanna I., additional, Lees, Jacqueline, additional, Lenzi, Renato, additional, Lerman, Caryn, additional, Lipton, Allan, additional, Loprinzi, Charles L., additional, Lozanski, Gerard, additional, Lustig, Robert, additional, Machtay, Mitchell, additional, Maity, Amit, additional, Malik, Uzma, additional, Manatt, C. Scott, additional, Mansour, John C., additional, Massion, Pierre P., additional, Mayer, R. Samuel, additional, McCormick, Beryl, additional, McDonald, Charles J., additional, McDougall, Ross, additional, McKenna, W. Gillies, additional, Meranze, Steven, additional, Metz, James M., additional, Meyskens, Frank L., additional, Michelassi, Fabrizio, additional, Mikkilineni, Radha, additional, Mock, Victoria, additional, Mohiuddin, Mohammed, additional, Montie, James, additional, Morton, A. Ross, additional, Murgo, Anthony J., additional, Neff, James R., additional, Nelson, William G., additional, Nesbit, Suzanne, additional, Niederhuber, John E., additional, O'Connor, Tracey, additional, O'Dorisio, Thomas, additional, Offit, Kenneth, additional, Onciu, Mihaela, additional, O'Reilly, Eileen M., additional, Ostrander, Elaine A., additional, O'Sullivan, Brian, additional, Pardoll, Drew M., additional, Park, Catherine K., additional, Patterson, Freda, additional, Pavletic, Steven Z., additional, Perry, Michael C., additional, Peterson, LoAnn C., additional, Phillips, Peter C., additional, Piantadosi, Steven, additional, Pili, Robert, additional, Pisters, Peter W.T., additional, Pittelkow, Mark R., additional, Plastaras, John P., additional, Platz, Elizabeth A., additional, Pribaz, Julian, additional, Pruitt, Amy A., additional, Pui, Ching-Hon, additional, Putnam, Joe Bill, additional, Quon, Harry, additional, Raber, Martin N., additional, Rajkumar, S. Vincent, additional, Regine, William F., additional, Ritter, Mark, additional, Roberts, John Robert, additional, Robinson-Bostom, Leslie, additional, Rodriguez, Ronald, additional, Rodriguez-Galindo, Carlos, additional, Rosenfeld, Myrna, additional, Rosenthal, Nadia, additional, Rubenstein, James L., additional, Rubin, Brian P., additional, Rupani, Reena, additional, Rusch, Valerie W., additional, Russell, Anthony H., additional, Ryan, Charles J., additional, Sacchini, Vergilio, additional, Sandler, Alan B., additional, Sandler, Howard, additional, Sandlund, John T., additional, Santana, Victor M., additional, Schnoll, Robert A., additional, Sciubba, Daniel M., additional, Seiden, Michael V., additional, Sekeres, Mikkael A., additional, Sharfman, William H., additional, Sharma, Ricky A., additional, Sideras, Kostandinos, additional, Silver, Kenneth, additional, Small, Eric J., additional, Smith, David C., additional, Sneed, Penny K., additional, Snow, Stephen N., additional, Sokoll, Lori J., additional, Sovak, Mika A., additional, Speyer, James L., additional, Spira, Alex I., additional, Springfield, Dempsey, additional, Spunt, Sheri L., additional, Stewart, Daniel, additional, Strickland, Paul T., additional, Sugden, Bill, additional, Sutcliffe, Siobhan, additional, Sun, Weijing, additional, Tallman, Martin S., additional, Talmadge, James E., additional, Tefferi, Ayalew, additional, Thom, Peter, additional, Thompson, Craig B., additional, Tisdale, Michael J., additional, Tobinai, Kensei, additional, Tomaszewski, Joseph E., additional, Topalian, Suzanne L., additional, Torti, Frank M., additional, Trump, Donald L., additional, Vallis, Katherine A., additional, Varadhachary, Gauri R., additional, Vemulapalli, Sreenivas, additional, Visvanathan, Kala, additional, Wagner-Johnston, Nina D., additional, Wahl, Richard L., additional, Watanabe, Toshiki, additional, Weber, Barbara L., additional, Weber, Sharon, additional, Weigel, Ronald J., additional, Weissman, Irving L., additional, Westra, William, additional, Wilson, Kathleen S., additional, Wilson, Wyndham H., additional, Wolff, Antonio C., additional, Wong, Sandra L., additional, Wood, Gary S., additional, Wyatt, Lance S., additional, Zakarija, Anaadriana, additional, Zaks, Tal Z., additional, and Zell, Jason A., additional
- Published
- 2008
- Full Text
- View/download PDF
8. Tumor Lysis Syndrome
- Author
-
Hochberg, Jessica, primary, Cairo, Mitchell S., additional, and Coccia, Peter F., additional
- Published
- 2008
- Full Text
- View/download PDF
9. Neonatal Leukocyte Physiology and Disorders
- Author
-
Parravicini, Elvira, primary, Ven, Carmella van de, additional, and Cairo, Mitchell S., additional
- Published
- 2005
- Full Text
- View/download PDF
10. Contributors
- Author
-
Adams-Chapman, Ira, primary, Ades, Anne M., additional, Ahmed, Amina, additional, Albers, Simone, additional, Allen, Marilee C., additional, Andrew, Maureen, additional, Back, Stephen A., additional, Baldwin, H. Scott, additional, Ballard, Philip L., additional, Ballard, Roberta A., additional, Banks-Randall, Beverly A., additional, Baumgart, Stephen, additional, Beckerman, Karen P., additional, Benedetti, Thomas J., additional, Berry, Gerard T., additional, Berseth, Carol Lynn, additional, Bethin, Kathleen E., additional, Bianchi, Diana W., additional, Cairo, Mitchell S., additional, Caldamone, Anthony, additional, Chandra, Sudhish, additional, Chmait, Ramen, additional, Clyman, Ronald I., additional, Cohen, Bernard A., additional, Cohen, Meryl S., additional, Cohen, Mitchell I., additional, Cohn, Robert M., additional, Cole, F. Sessions, additional, Corbet, Anthony, additional, Denne, Scott C., additional, Di Maggio, Theresa J., additional, Eichenwald, Eric C., additional, Evans, Jacquelyn R., additional, Evans, Nick, additional, Fanaroff, Avroy A., additional, Ferriero, Donna M., additional, Fisher, Delbert A., additional, Flores-Sarnat, Laura, additional, Friedlich, Philippe S., additional, Gaynor, J. William, additional, Gest, Alfred L., additional, Geva, Tal, additional, Gibbons, Mary Ann E., additional, Gilbert, William M., additional, Glader, Bertil E., additional, Gleason, Christine A., additional, Goldberg, Michael J., additional, Good, William V., additional, Goodwin, Gregory, additional, Gopalani, Sameer, additional, Greene, Carol L., additional, Grottkau, Brian E., additional, Gruber, Peter J., additional, Guignard, Jean-Pierre, additional, Guttentag, Susan, additional, Hamrick, Shannon E.G., additional, Hansen, Thomas N., additional, Hostetter, Margaret K., additional, Hughes, Samuel C., additional, Hull, Andrew D., additional, Jedeikin, Roy, additional, Juul, Sandra E., additional, Kaplan, Bernard S., additional, Kaplan, Paige, additional, Kazin, Rebecca A., additional, Kelly, Thomas F., additional, Kuhle, Stefan, additional, Laing, Ian A., additional, Levy, Harvey L., additional, Loh, Mignon L., additional, Lorch, Scott A., additional, Lugo, Ralph A., additional, Machin, Geoffrey A., additional, MacMahon, James R., additional, Macones, George A., additional, Madan, Ashima, additional, Marino, Bradley S., additional, Martinez, Alma, additional, Maschoff, Kathryn L., additional, Massicotte, Patricia, additional, Matthay, Katherine K., additional, Mentzer, William C., additional, Merrill, Jeffrey D., additional, Miller, Carol A., additional, Mitchell, Lesley, additional, Moise, Alicia A., additional, Mollen, Thomas J., additional, Monahan, Timothy P., additional, Moore, Thomas R., additional, Muglia, Louis J., additional, Nelson, Robert M., additional, Newman, Thomas B., additional, Pallotto, Eugenia K., additional, Pan, Erica S., additional, Parravicini, Elvira, additional, Partridge, J. Colin, additional, Poenaru, Dan, additional, Poindexter, Brenda B., additional, Polin, Richard A., additional, Polk, Daniel H., additional, Pursley, DeWayne M., additional, Ramanathan, Rangasamy, additional, Ramierez-Schrempp, Daniela, additional, Regan, Joan A., additional, Richard, Elisabeth G., additional, Robertson, Richard L., additional, Rosen, Mark A., additional, Rubin, Lewis P., additional, Rychik, Jack, additional, Saitta, Sulagna C., additional, Sánchez, Pablo J., additional, Sarnat, Harvey B., additional, Schanler, Richard J., additional, Scher, Mark S., additional, Seri, Istvan, additional, Siegfried, Elaine C., additional, Silverman, Gary A., additional, Simmons, Rebecca, additional, Sniderman, Susan, additional, Spray, Thomas L., additional, Stanley, Charles A., additional, Stevenson, David K., additional, Stoll, Barbara J., additional, Taeusch, H. William, additional, Tarczy-Hornoch, Peter, additional, Taylor, George A., additional, Thomas, Janet A., additional, Tulassay, Tivadar, additional, van de Ven, Carmella, additional, Vohr, Betty R., additional, Ward, Robert M., additional, Weintrub, Peggy Sue, additional, Welty, Stephen, additional, Wernovsky, Gil, additional, Williams, Calvin B., additional, Wright, Linda L., additional, Young, Alison Z., additional, Zackai, Elaine H., additional, and Zderic, Stephen A., additional
- Published
- 2005
- Full Text
- View/download PDF
11. List of Contributors
- Author
-
Barclay, Sheilagh, primary, Bowman, Laura C., additional, Briones, Michael C., additional, Burghardt, David C., additional, Cairo, Mitchell S., additional, Clark, Kenneth A., additional, Di Paola, Jorge A., additional, Eder, Anne F., additional, Friedman, David F., additional, Gorlin, Jed B., additional, Grindon, Alfred J., additional, Haight, Ann E., additional, Harrison, Lauren, additional, Hillyer, Christopher D., additional, Hillyer, Krista L., additional, Hume, Heather A., additional, Jamali, Faranak, additional, Josephson, Cassandra D., additional, Johnson, Susan T., additional, Kao, Grace S., additional, Kim, Haewon C., additional, King, Karen E., additional, Lögdberg, Lennart E., additional, McLeod, Bruce C., additional, Montenegro, Lisa M., additional, Ness, Paul M., additional, Nuyt, Anne-Monique, additional, Panagopoulos, Alexandros, additional, Pisciotto, Patricia T., additional, Pugh, Tina M., additional, Raife, Thomas J., additional, Ramasethu, Jayashree, additional, Roback, John D., additional, Robitaille, Nancy, additional, Sandler, S. Gerald, additional, Saxonhouse, Matthew, additional, Slayton, William, additional, Sloan, Steven, additional, Sola, Martha C., additional, Strauss, Ronald G., additional, Sulis, Maria Luisa, additional, Wicklund, Brian M., additional, and Wong, Edward C.C., additional
- Published
- 2004
- Full Text
- View/download PDF
12. Neonatal Neutrophil Normal and Abnormal Physiology
- Author
-
Parravicini, Elvira, primary, van de Ven, Carmella, additional, and Cairo, Mitchell S., additional
- Published
- 2004
- Full Text
- View/download PDF
13. CONTRIBUTORS
- Author
-
Abbasi, Soraya, primary, Abman, Steven H., additional, Adamson, S. Lee, additional, Adzick, N. Scott, additional, Albertine, Kurt H., additional, Alman, Benjamin A., additional, Altschuler, Steven M., additional, Anderson, Page A.W., additional, Anthony, Russell V., additional, Aron, Elisabeth A., additional, Aslan, Ahmet R., additional, Asselin, Jeanette M., additional, Auten, Richard L., additional, Avery, Mary Ellen, additional, Avner, Ellis D., additional, Baldwin, H. Scott, additional, Ballard, Philip L., additional, Bancalari, Eduardo, additional, Barker, David J.P., additional, Barker, Pierre M., additional, Battaglia, Frederick C., additional, Beauchamp, Gary K., additional, Beesley, Jacqueline, additional, Benchimol, Corinne, additional, Bennet, Laura, additional, Berg, Robert A., additional, Berry, Gerard T., additional, Berseth, Carol Lynn, additional, Bhutani, Vinod K., additional, Blecher, Stan R., additional, Blood, Arlin B., additional, Bolender, David L., additional, Boyd, Robert D.H., additional, Brace, Robert A., additional, Brewer, Eileen D., additional, Brophy, Patrick D., additional, Broussard, Delma L., additional, Bucuvalas, John C., additional, Burrin, Douglas G., additional, Byrne, Bridgette M.P., additional, Byskov, Anne Grete, additional, Cairo, Mitchell S., additional, Cannon, Barbara, additional, Caplan, Michael S., additional, Caplin, Neil, additional, Carlson, Susan E., additional, Carlton, David P., additional, Cashore, William J., additional, Chaiworapongsa, Tinnakorn, additional, Chemtob, Sylvain, additional, Chevalier, Robert L., additional, Chheda, Sadhana, additional, Christensen, Robert D., additional, Chu, David H., additional, Clancy, Robert Ryan, additional, Clandinin, M. Thomas, additional, Clark, David A., additional, Cleary-Goldman, Jane, additional, Clyman, Ronald I., additional, Cohen, Pinchas, additional, Corey, Howard E., additional, Cotton, Robert B., additional, Cowart, Beverly J., additional, Cowett, Richard M., additional, Crombleholme, Timothy M., additional, Crowe, James E., additional, Cuttler, Leona, additional, D'Alton, Mary E., additional, Danzer, Enrico, additional, De León, Diva D., additional, Delivoria-Papadopoulos, Maria, additional, Diaz, George A., additional, Dickinson, Chris J., additional, Dormans, John P., additional, Durand, David J., additional, Edwards, A. David, additional, Ennever, John F., additional, Erickson, Robert P., additional, Erol, Bulent, additional, Fahim, Mohamed A., additional, Feld, Leonard G., additional, Feldman, Miguel, additional, Fernandez, Lucas G., additional, Field, Douglas G., additional, Fisher, Delbert A., additional, Fox, William W., additional, Frank, Hans-Georg, additional, Friedlich, Philippe S., additional, Friedman, Aaron L., additional, Friedman, Joshua R., additional, Garland, Marianne, additional, Gervasi, Maria-Teresa, additional, Gibson, James B., additional, Gluckman, P.D., additional, Goldberg, Michael J., additional, Goldman, Armond S., additional, Goldstein, Gary W., additional, Gomez, R. Ariel, additional, Gondos, Bernard, additional, Grant, Denis M., additional, Green, Lucy R., additional, Greenspan, Jay S., additional, Grimberg, Adda, additional, Grindley, Justin C., additional, Gross, Ian, additional, Guignard, Jean-Pierre, additional, Gunn, Alistair J., additional, Haddad, Gabriel G., additional, Hagstrom, J. Nathan, additional, Halpern, Kathrin V., additional, Hambidge, K. Michael, additional, Hamosh, Margit, additional, Hanson, Mark A., additional, Haramati, Aviad, additional, Harding, Richard, additional, Harris, Mary Catherine, additional, Haxhiu, Musa A., additional, Hay, William W., additional, Hayward, Anthony R., additional, Heird, William C., additional, Herrera, Emilio, additional, Hill, Harry R., additional, Hillemeier, A. Craig, additional, Hirschhorn, Kurt, additional, Hoath, Steven B., additional, Horst, David A., additional, Hunley, Tracy E., additional, Hunter, Christian J., additional, Husain, Shahid M., additional, Hutson, Susan M., additional, Ikegami, Machiko, additional, Inder, Terrie E., additional, Jobe, Alan H., additional, Johnson, Lois H., additional, Johnston, Michael V., additional, Johnston, Richard B., additional, Jones, Deborah P., additional, Jones, Peter Lloyd, additional, Jose, Pedro A., additional, Kalhan, Satish C., additional, Kallapur, Suhas, additional, Kaplan, Stanley, additional, Karpen, Saul J., additional, Kashyap, Sudha, additional, Kaskel, Frederick J., additional, Levitt Katz, Lorraine E., additional, Kaufmann, Peter, additional, Keeney, Susan E., additional, Kilpatrick, Laurie, additional, Kinsella, John P., additional, Kirby, Margaret L., additional, Kleinman, Charles S., additional, Kogan, Barry A., additional, Koldovský, Otakar, additional, Kon, Valentina, additional, Kopecky, Ernest A., additional, Korchak, Helen M., additional, Koren, Gideon, additional, Krebs, Nancy F., additional, Kulik, Thomas J., additional, Kutikov, Jessica Katz, additional, La Pine, Timothy R., additional, Lasunción, Miguel Angel, additional, Laterra, John, additional, Lee, P.C., additional, Levine, Fred, additional, Lewis, David B., additional, Liacouras, Chris A., additional, Linshaw, Michael A., additional, Lister, George, additional, Loomis, Cynthia A., additional, Lorenz, John M., additional, Lobritto, Steven, additional, Lugo, Ralph A., additional, Maheshwari, Akhil, additional, Manco-Johnson, Marilyn J., additional, Mantilla, Carlos B., additional, Mariscalco, M. Michele, additional, Maródi, László, additional, Maršál, Karel, additional, Martin, Richard J., additional, Matthews, Dwight E., additional, McDuffie, Marcia, additional, McGowan, Jane E., additional, McManaman, James, additional, Mehmet, Huseyin, additional, Mennella, Julie A., additional, Metinko, Andrew, additional, Miller, Martha J., additional, Monagle, Paul, additional, Mortola, Jacopo P., additional, Mott, Glen E., additional, Mughal, M. Zulficar, additional, Mulroney, Susan E., additional, Munshi, Upender K., additional, Myatt, Leslie, additional, Myers, Margaret A., additional, Namgung, Ran, additional, Narkewicz, Michael R., additional, Nau, Heinz, additional, Nedergaard, Jan, additional, Neville, Margaret C., additional, Nielsen, Heber C., additional, Nogee, Lawrence M., additional, Noori, Shahab, additional, Norwitz, Errol R., additional, Norwood, Victoria F., additional, Ogata, Edward S., additional, Ohls, Robin K., additional, Olson, Thomas A., additional, Omari, Taher I., additional, Padbury, James F., additional, Palmert, Mark R., additional, Parravicini, Elvira, additional, Pereira, Gilberto R., additional, Perlman, Jeff M., additional, Philipps, Anthony F., additional, Pickoff, Arthur S., additional, Pinal, C.S., additional, Pleasure, David, additional, Pleasure, Jeanette, additional, Plonait, Sabine Luise, additional, Polin, Richard A., additional, Polk, Daniel H., additional, Pomeroy, Scott L., additional, Possmayer, Fred, additional, Post, Martin, additional, Power, Gordon G., additional, Prada, Jorge A., additional, Putet, Guy, additional, Pysher, Theodore J., additional, Quinn, Graham E., additional, Rabinovitch, Marlene, additional, Randell, Scott H., additional, Regnault, Timothy R.H., additional, Rieder, Michael J., additional, Rigatto, Henrique, additional, Rintoul, Natalie E., additional, Robillard, Jean E., additional, Robinson, Julian, additional, Romero, Roberto, additional, Rooney, Seamus A., additional, Rose, James C., additional, Rosenfeld, Charles R., additional, Ross, Arthur J., additional, Rudolph, Colin D., additional, Sahni, Rakesh, additional, Sarnat, Harvey B., additional, Satlin, Lisa M., additional, Saugstad, Ola Didrik, additional, Schibler, Kurt R., additional, Schulze, Karl, additional, Schwartz, Jeffrey, additional, Sedin, Gunnar, additional, Segar, Jeffrey L., additional, Seri, Istvan, additional, Setchell, Kenneth, additional, Shaffer, Thomas H., additional, Shaul, Philip W., additional, Shenai, Jayant P., additional, Sibley, Colin P., additional, Sieck, Gary C., additional, Siler-Khodr, Theresa M., additional, Silverstein, Faye S., additional, Simmons, Rebecca A., additional, Sivieri, Emidio M., additional, Slavkin, Harold C., additional, Snyder, Evan Y., additional, Snyder, Jeanne M., additional, Solhaug, Michael J., additional, Southern, Kevin W., additional, Spitzer, Adrian, additional, Spitzer, Alan R., additional, Stanley, Charles A., additional, Stapleton, F. Bruder, additional, Styne, Dennis, additional, Sweeney, William E., additional, Talner, Norman S., additional, Thornton, Paul S., additional, Truog, William Edward, additional, Tsang, Reginald C., additional, Tufro, Alda, additional, Ullrich, Nicole J., additional, Un, Socheata, additional, Van Aerde, John E., additional, van de Ven, Carmella, additional, van Goudoever, Johannes B., additional, Vannucci, Robert C., additional, Vannucci, Susan J., additional, van Tuyl, Minke, additional, Volpe, Joseph J., additional, Wallin, Reidar, additional, Warburton, David, additional, Ward, Robert M., additional, Weitkamp, Joern-Hendrik, additional, Werlin, Steven L., additional, Werner, Lynne A., additional, Wert, Susan E., additional, Westergaard, Lars Grabow, additional, Whitsett, Jeffrey A., additional, Wilke, Michaelann, additional, Williams, John V., additional, Williamson, Dermot H., additional, Winkelstein, Jerry A., additional, Winter, Jeremy S.D., additional, Woelkers, Douglas A., additional, Wolfson, Marla R., additional, Woroniecki, Robert P., additional, Yassir, Walid K., additional, Yip, Stephen, additional, Yoder, Mervin C., additional, Young, Sharla, additional, Young, Stephen L., additional, and Zhou, Dan, additional
- Published
- 2004
- Full Text
- View/download PDF
14. Granulocyte Transfusions in the Neonate and Child
- Author
-
Sulis, Maria Luisa, primary, Harrison, Lauren, additional, and Cairo, Mitchell S., additional
- Published
- 2004
- Full Text
- View/download PDF
15. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel.
- Author
-
Perissinotti AJ, Bishop MR, Bubalo J, Geyer MB, Goodrich A, Howard SC, Kula J, Mandayam S, Cairo MS, and Pui CH
- Abstract
Introduction: Tumor lysis syndrome (TLS), which occurs spontaneously or in response to anticancer treatment, results in the release of intracellular potassium, phosphorus, and nucleic acids into the bloodstream, which results in secondary clinical complications that may be fatal. Prior TLS guidelines do not take into consideration potent novel oncologic agents or contemporary treatment paradigms with increased risk of TLS. Thus, a modified Delphi panel of experts was convened to provide an update for TLS management guidelines based upon a combination of supporting literature and practice consensus., Methods: A three-round modified Delphi process was implemented. For round 1, nine expert panelists completed a web-based questionnaire developed using published literature. In round 2, panelists were asked to reconsider their answers to questions that did not reach consensus (defined as ≥ 66% agreement among voting panelists). Round 3 was an unblinded, moderated virtual meeting to discuss any remaining questions that did not reach consensus., Results: Detailed recommendations are given for prophylaxis, monitoring, and management of TLS risks and complications, with hydration being a key element of TLS prophylaxis and management. Guidelines for the management of acute effects of TLS and prevention of long-term renal effects include management of hyperkalemia, hypocalcemia, hyperphosphatemia, and hyperuricemia., Discussion: Although the control of uric acid levels is quite effective with currently available agents, panelists emphasize the importance of monitoring and treating other dangerous electrolyte abnormalities such as hyperkalemia and hyperphosphatemia. Guidelines from this modified Delphi panel should aid clinicians in preventing and managing TLS., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AJP reports consulting fees from AbbVie, BeiGene, Pfizer, Sanofi-Aventis, and Servier. MRB serves as a member on an advisory board or as a consultant for Autolus Therapeutics, BMS/JUNO Therapeutics, Chimeric Therapeutics, CRISPR Therapeutics, IN8bio, Incyte, Iovance Biotherapeutics, KITE/Gilead, Novartis, PhysIQ, and Sana Biotechnology and is on the speakers’ bureau for ADC Therapeutics, Agios, BMS, Kite/Gilead, Incyte, Sanofi, and Servier. JB reports consulting fees from Sanofi-Aventis. MBG reports research support from Actinium Pharmaceuticals, Amgen, and Sanofi and has served on an advisory board for Sanofi and as a consultant for Novartis. AG reports consulting fees from Sanofi-Aventis. SCH has served as a speaker for Jazz Pharma and Sanofi, has received grant funding from Jazz Pharma, and has served as a consultant for Servier. JK reports consulting fees from Sanofi-Aventis. SM reports grant funding from Horizon; service on advisory boards for Calliditas, Chinook, Travere, and US Renal Care; and service on speaker’s bureaus for Bayer and Calliditas. MSC serves on the speaker’s bureau and as a consultant for Sanofi. C-HP reports support by grant CA21765 from the National Cancer Institute and American Lebanese Syrian Associated Charities, and honorarium from Amgen and Novartis., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
16. "The state of the science" of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL).
- Author
-
Cairo MS
- Subjects
- Humans, Adolescent, Young Adult, Lymphoma, Non-Hodgkin
- Published
- 2023
- Full Text
- View/download PDF
17. Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults.
- Author
-
Goldman S and Cairo MS
- Subjects
- Humans, Child, Adolescent, Young Adult, B-Lymphocytes, Germinal Center, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse therapy
- Abstract
Mature B-cell lymphoma in children, adolescents and young adults comprises three major histological subtypes including in order of frequency Burkitt, germinal center diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. The cure rate of the first two with aggressive short chemotherapy based on clinical grouping is ∼90% in resource rich countries. Recent data has shown that incorporation of immune therapy has enhanced event free survival in advanced patients. Future studies will address the possibility of reducing the burden of chemotherapy by substitution of immune based therapies., Competing Interests: Declaration of competing interest SG is on the Speaker Bureau for Jazz Pharmaceuticals. MSC has served as a consultant for Jazz Pharmaceuticals, Omeros Pharmaceuticals, Servier Pharmaceuticals, NEKTAR and Novartis Pharmaceuticals; Speakers Bureau for Jazz Pharmaceuticals, Servier Pharmaceuticals, Amgen, Inc., Sanofi and Sobi; Advisory Board for Astra Zeneca; and research funding from Celularity, Merck, Miltenyi Biotec, Servier, Omeros and Jazz., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.
- Author
-
Chu Y, Gardenswartz A, Diorio C, Marks LJ, Lowe E, Teachey DT, and Cairo MS
- Subjects
- Young Adult, Humans, Child, Adolescent, Immunotherapy, Killer Cells, Natural pathology, Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Non-Hodgkin drug therapy, Antineoplastic Agents therapeutic use, Immunoconjugates therapeutic use
- Abstract
The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately needed for this poor-risk population. CD19, CD20, CD22, CD79a, CD38, CD30, LMP1 and LMP2 are attractive targets for immunotherapy in CAYA patients with R/R NHL. Novel anti-CD20 monoclonal antibodies, anti-CD38 monoclonal antibody, antibody drug conjugates and T and natural killer (NK)-cell bispecific and trispecific engagers are being investigated in the R/R setting and are changing the landscape of NHL therapy. A variety of cellular immunotherapies such as viral activated cytotoxic T-lymphocyte, chimeric antigen receptor (CAR) T-cells, NK and CAR NK-cells have been investigated and provide alternative options for CAYA patients with R/R NHL. Here, we provide an update and clinical practice guidance of utilizing these cellular and humoral immunotherapies in CAYA patients with R/R NHL., Competing Interests: Declaration of competing interest M.S.C. has served as a consultant for Jazz Pharmaceuticals, Omeros Pharmaceuticals, Servier Pharmaceuticals, NEKTAR and Novartis Pharmaceuticals; Speakers Bureau for Jazz Pharmaceuticals, Servier Pharmaceuticals, Amgen, Inc., Sanofi and Sobi; Advisory Board for Astra Zeneca; and research funding from Celularity, Merck, Miltenyi Biotec, Servier, Omeros and Jazz. DTT has served on Advisory Boards for Jazz Pharmaceuticals, BEAM Therapeutics, and Sobi. DTT receives research funding from Jazz Pharmaceuticals, Servier, BEAM Therapeutics and NeoImmune Tech. DTT has multiple patents pending in CAR-T. EJL has served as consultant to Pfizer. All other co-authors have no conflict of interest to declare., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
19. EBV: the virus that keeps on giving!
- Author
-
Cairo MS
- Subjects
- Humans, Child, Herpesvirus 4, Human, Epstein-Barr Virus Infections complications, Lymphoma complications
- Published
- 2023
- Full Text
- View/download PDF
20. KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial.
- Author
-
Pulsipher MA, Ahn KW, Bunin NJ, Lalefar N, Anderson E, Flower A, Cairo MS, Talano JA, Chaudhury S, Kitko CL, Duke JL, Monos D, Leung W, Dvorak CC, and Abdel-Azim H
- Subjects
- Humans, Child, Prospective Studies, Transplantation Conditioning, Receptors, KIR, Antigens, CD19, Receptors, Antigen, T-Cell, alpha-beta, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease etiology, Myelodysplastic Syndromes therapy, Leukemia, Myeloid, Acute therapy
- Abstract
We performed a prospective multicenter study of T-cell receptor αβ (TCR-αβ)/CD19-depleted haploidentical hematopoietic cell transplantation (HCT) in children with acute leukemia and myelodysplastic syndrome (MDS), to determine 1-year disease-free survival (DFS) and compare 2-year outcomes with recipients of other donor cell sources. Fifty-one patients aged 0.7 to 21 years were enrolled; donors were killer immunoglobulin-like receptor (KIR) favorable based on ligand mismatch and/or high B content. The 1-year DFS was 78%. Superior 2-year DFS and overall survival (OS) were noted in patients <10 years of age, those treated with reduced toxicity conditioning (RTC) rather than myeloablative conditioning, and children with minimal residual disease <0.01% before HCT. Multivariate analysis comparing the KIR-favorable haploidentical cohort with controls showed similar DFS and OS compared with other donor cell sources. Multivariate analysis also showed a marked decrease in the risk of grades 2 to 4 and 3 to 4 acute graft versus host disease (aGVHD), chronic GVHD, and transplant-related mortality vs other donor cell sources. Ethnic and racial minorities accounted for 53% of enrolled patients, and data from a large cohort of recipients/donors screened for KIR showed that >80% of recipients had a KIR-favorable donor by our definition, demonstrating that this approach is broadly applicable to groups often unable to find donors. This prospective, multicenter study showed improved outcomes using TCR-αβ/CD19-depleted haploidentical donors using RTC for children with acute leukemia and MDS. Randomized trials comparing this approach with matched unrelated donors are warranted. This trial was registered at https://clinicaltrials.gov as #NCT02646839., (© 2022 by The American Society of Hematology.)
- Published
- 2022
- Full Text
- View/download PDF
21. A new Burkitt "look-alike" lymphoma.
- Author
-
Cairo MS
- Subjects
- Chromosome Aberrations, Humans, Mutation, Burkitt Lymphoma
- Abstract
Competing Interests: Conflict-of-interest disclosure: The author declares no competing financial interests.
- Published
- 2019
- Full Text
- View/download PDF
22. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
- Author
-
Cairo MS, Thompson S, Tangirala K, and Eaddy MT
- Subjects
- Allopurinol therapeutic use, Female, Gout Suppressants therapeutic use, Humans, Hyperuricemia drug therapy, Hyperuricemia economics, Male, Middle Aged, Retrospective Studies, Tumor Lysis Syndrome drug therapy, Urate Oxidase therapeutic use, Uric Acid metabolism, Allopurinol economics, Gout Suppressants economics, Hospitalization economics, Length of Stay economics, Tumor Lysis Syndrome economics, Urate Oxidase economics
- Abstract
Background: The aim of the study was to compare reductions in uric acid (UA), length of stay (LOS), and hospitalization costs in patients with tumor lysis syndrome (TLS) treated with rasburicase or allopurinol., Patients and Methods: This retrospective study of administrative data included hospitalized pediatric and adult patients who had clinical or laboratory TLS and received rasburicase or allopurinol. Each rasburicase-treated patient was propensity score-matched with 4 allopurinol-treated patients. Mean changes in UA within ≤ 2 days of treatment initiation were determined. Economic outcomes included mean number of days in the intensive care unit (ICU), total LOS, costs/hospitalization, and costs/percentage change in UA., Results: Twenty-six rasburicase-treated patients were matched with 104 allopurinol-treated patients. Reduction in plasma UA was 5.3 mg/dL greater for patients treated with rasburicase than for patients treated with allopurinol (P < .0001). Length of ICU stay was 2.5 days less for patients treated with rasburicase than for patients treated with allopurinol (P < .0001), and total LOS was 5 days less for patients treated with rasburicase than for patients treated with allopurinol (P = .02). Total costs per patient were $20,038 lower for patients treated with rasburicase than for patients treated with allopurinol (P < .02). Cost per percentage UA reduction was also lower for patients treated with rasburicase versus patients treated with allopurinol ($3899 vs. $16,894; P < .001)., Conclusion: In this analysis of TLS patients who received care in real-world settings, rasburicase versus allopurinol was significantly more effective in treating hyperuricemia and was associated with significantly shorter ICU and overall hospital stays and lower total inpatient costs., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
23. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
- Author
-
Satwani P, Bavishi S, Saha A, Zhao F, Ayello J, van de Ven C, Chu Y, and Cairo MS
- Subjects
- Animals, Gene Expression Regulation, Neoplastic drug effects, Histocompatibility Antigens Class I metabolism, Humans, Jurkat Cells, Killer Cells, Natural immunology, Ligands, Lymphoma, Non-Hodgkin immunology, Lymphoma, Non-Hodgkin metabolism, Male, Mice, Mice, Inbred NOD, Mice, SCID, Mice, Transgenic, NK Cell Lectin-Like Receptor Subfamily K metabolism, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma metabolism, Transcriptional Activation drug effects, Tumor Cells, Cultured, Up-Regulation drug effects, Cytotoxicity, Immunologic drug effects, Cytotoxicity, Immunologic genetics, Depsipeptides pharmacology, Histocompatibility Antigens Class I genetics, Killer Cells, Natural drug effects, Lymphoma, Non-Hodgkin genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
- Abstract
Background Aims: There is a critical need to prevent and/or treat hematological relapse after allogeneic hematopoietic stem cell transplantation. The activating NKG2D receptor expressed on natural killer (NK) cells, when engaged by its corresponding ligands (MIC A/B), activates NK cells to become cytotoxic against malignant cells., Methods: We incubated acute lymphoblastic leukemia and non-Hodgkin lymphoma cells for 24 h with 10 ng/mL of romidepsin. Flow cytometry was performed to demonstrate changes in surface expression of NKG2D ligands MIC A/B. In vitro and in vivo cytotoxicity was measured by means of modified Europium assay, and non-obese diabetic/severe combined immunodeficiency mice were xenografted with RS 4:11 cells., Results: We demonstrated an approximately 50, 200, 1300 and 180-fold increase in the number of cells positive for the surface expression of MIC A/B in RS 4:11 (P < 0.001), REH (P < 0.001), Ramos (P < 0.001) and Jurkat cells (P < 0.001), respectively. We further demonstrated a significant increase in NK cell-mediated in vitro cytotoxicity against RS 4:11 (P < 0.004), Ramos (P < 0.05), Jurkat (P < 0.001) and REH cells (P < 0.01), respectively. Romidepsin-mediated NK cytotoxicity was blocked by pre-incubating NK cells with anti-NKG2D-Fc in RS 4:11 (P < 0.03) and Ramos cells (P < 0.01), respectively. Finally, non-obese diabetic/severe combined immunodeficiency mice xenografted with RS 4:11 cells had a significant increase in survival (P < 0.02) in mice treated with romidepsin and interleukin-2-activated NK cells compared with each of these other treatment groups., Conclusions: Romidepsin significantly enhanced in vitro and in vivo NK cell cytotoxicity mediated in part by increased MIC A/B expression on malignant cells. This translational approach of the use of romidepsin and interleukin-2-activated NK cells should be considered in patients with relapsed/refractory leukemia or lymphoma., (Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
24. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
- Author
-
Hochberg J, El-Mallawany NK, and Cairo MS
- Subjects
- Adolescent, Adoptive Transfer, Adult, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Murine-Derived therapeutic use, Antigens, CD19, Antigens, CD20, Child, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Receptors, Antigen, T-Cell genetics, Recombinant Fusion Proteins genetics, Rituximab, Sialic Acid Binding Ig-like Lectin 2 antagonists & inhibitors, Young Adult, Immunotherapy methods, Molecular Targeted Therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
- Abstract
Although the event-free survival for children and adolescents with acute lymphoblastic leukemia (ALL) has dramatically improved over the past half century, it has plateaued over the past decade. Children and adolescents with refractory/relapsed ALL continue to have a dismal prognosis with hematopoietic stem cell transplant being their most viable option for cure. There is an obvious need for the development of novel agents to further enhance overall outcomes. In this review we focus on the development of humoral and cellular immunotherapeutic agents in the treatment of childhood, adolescent, and young adult ALL. Immunotherapy in various forms has shown immense promise. To date we have seen numerous safety studies using monoclonal antibody therapy, antibody conjugates, bispecific T cell and bispecific natural killer (NK) cell antibodies and genetically reengineered T and NK cells expressing targeted chimeric antigen receptors. Initial success has been found with the anti-CD20 monoclonal antibodies followed by promising results using anti-CD22 and anti-CD19 therapies alone or in combination. Genetic modification of T and NK cells to express targeted chimeric antigen receptors offers a novel immunotherapy option that demonstrates enhanced cytotoxicity in otherwise resistant tumor cells. There is great potential to combine immunotherapies to further improve overall cure rates in children, adolescents, and young adults with poor-risk ALL. A number of humoral and cellular immunotherapy strategies have been investigated and found to be effective, safe, and well tolerated. Ideally, the targeted approach of immunotherapy will result in an overall decrease in toxicities experienced by patients. Future studies are required to determine when in the course of treatment with humoral and cellular therapy will have the safest and optimal effect in ALL., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
25. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.
- Author
-
Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, and Davies SM
- Subjects
- Adolescent, Child, Child, Preschool, Female, Humans, Leukemia, Myeloid, Acute mortality, Male, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Hematopoietic Stem Cell Transplantation adverse effects, Leukemia, Myeloid, Acute therapy
- Abstract
The safety and efficacy of reduced-intensity conditioning (RIC) regimens for the treatment of pediatric acute myeloid leukemia is unknown. We compared the outcome of allogeneic hematopoietic cell transplantation in children with acute myeloid leukemia using RIC regimens with those receiving myeloablative-conditioning (MAC) regimens. A total of 180 patients were evaluated (39 with RIC and 141 with MAC regimens). Results of univariate and multivariate analysis showed no significant differences in the rates of acute and chronic graft-versus-host disease, leukemia-free, and overall survival between treatment groups. The 5-year probabilities of overall survival with RIC and MAC regimens were 45% and 48%, respectively (P = .99). Moreover, relapse rates were not higher with RIC compared with MAC regimens (39% vs 39%; P = .95), and recipients of MAC regimens were not at higher risk for transplant-related mortality compared with recipients of RIC regimens (16% vs 16%; P = .73). After carefully controlled analyses, we found that in this relatively modest study population, the data supported a role for RIC regimens for acute myeloid leukemia in children undergoing allogeneic hematopoietic cell transplantation. The data also provided justification for designing a carefully controlled randomized clinical trial that examines the efficacy of regimen intensity in this population.
- Published
- 2014
- Full Text
- View/download PDF
26. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy.
- Author
-
Gerrard M, Waxman IM, Sposto R, Auperin A, Perkins SL, Goldman S, Harrison L, Pinkerton R, McCarthy K, Raphael M, Patte C, and Cairo MS
- Subjects
- Adolescent, Child, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Lymphoma, Large B-Cell, Diffuse mortality, Male, Mediastinal Neoplasms mortality, Neoplasm Staging, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse pathology, Mediastinal Neoplasms drug therapy, Mediastinal Neoplasms pathology
- Abstract
Mediastinal large B-cell lymphoma (MLBL) represents 2% of mature B-cell non-Hodgkin lymphoma in patients ≤ 18 years of age. We analyzed data from childhood and adolescent patients with stage III MLBL (n = 42) and non-MLBL DLBCL (n = 69) treated with Group B therapy in the French-American-British/Lymphome Malins de Burkitt (FAB/LMB) 96 study. MLBL patients had a male/female 26/16; median age, 15.7 years (range, 12.5-19.7); and LDH < 2 versus ≥ 2 × the upper limit of normal, 23:19. Six MLBL patients (14%) had < a 20% response to initial COP (cyclophosphamide, vincristine, and prednisone) therapy. Central pathology revealed approximately 50% with classical features of primary MLBL. Five-year event-free survival for the stage III MLBL and non-MLBL DLBCL groups was 66% (95% confidence interval [CI], 49%-78%) and 85% (95% CI, 71%-92%), respectively (P < .001; 14%). The 5-year overall survival in the 42 MLBL patients was 73% (95% CI, 56%-84%). We conclude that MLBL in adolescent patients is associated with significantly inferior event-free survival compared with stage III non-MLBL DLBCL and can be of multiple histologies. Alternate treatment strategies should be investigated in the future taking into account both adult MLBL approaches and more recent biologic findings in adult MLBL.
- Published
- 2013
- Full Text
- View/download PDF
27. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
- Author
-
Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, and Hari PN
- Subjects
- Acute Disease, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chronic Disease, Combined Modality Therapy, Disease Progression, Disease-Free Survival, Female, Graft vs Host Disease epidemiology, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation adverse effects, Histocompatibility, Humans, Kaplan-Meier Estimate, Lymphoma, Large B-Cell, Diffuse drug therapy, Male, Middle Aged, Myeloablative Agonists adverse effects, Recurrence, Retrospective Studies, Transplantation, Homologous adverse effects, Treatment Outcome, Young Adult, Lymphoma, Large B-Cell, Diffuse surgery, Myeloablative Agonists administration & dosage, Transplantation Conditioning methods, Whole-Body Irradiation adverse effects
- Abstract
The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progression-free survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.
- Published
- 2012
- Full Text
- View/download PDF
28. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling.
- Author
-
Deffenbacher KE, Iqbal J, Sanger W, Shen Y, Lachel C, Liu Z, Liu Y, Lim MS, Perkins SL, Fu K, Smith L, Lynch J, Staudt LM, Rimsza LM, Jaffe E, Rosenwald A, Ott GK, Delabie J, Campo E, Gascoyne RD, Cairo MS, Weisenburger DD, Greiner TC, Gross TG, and Chan WC
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Burkitt Lymphoma classification, Child, Child, Preschool, Female, Gene Dosage genetics, Gene Rearrangement genetics, Humans, Loss of Heterozygosity genetics, Lymphoma, Large B-Cell, Diffuse classification, Lymphoma, Non-Hodgkin classification, Male, MicroRNAs genetics, Middle Aged, Polymorphism, Single Nucleotide genetics, Young Adult, Burkitt Lymphoma genetics, Gene Expression Profiling, Genomics, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Non-Hodgkin genetics
- Abstract
Burkitt lymphoma (BL) predominates in pediatric patients, whereas diffuse large B-cell lymphoma (DLBCL) is uncommon. In contrast to adults, BL and DLBCL are treated similarly in children and both entities have superior outcomes in children compared with adults. Gene expression profiling (GEP) and miRNA expression profiling clearly differentiated pediatric DLBCL from BL, forming distinct clusters regardless of patient age. However, pathway analysis of GEP data identified minor differences between corresponding pediatric and adult tumors. Predominance (6:1) of the germinal center B-cell subtype to activated B-cell subtype was found among pediatric DLBCL. Two cases were molecularly classified as primary mediastinal B-cell lymphoma. We observed frequent abnormalities in 8q24 in pediatric DLBCL, including MYC rearrangement in 31% (5 of 16) and gain or amplification in 50% (6 of 12) nonrearranged cases. MYC rearrangement was present in 96% (23 of 24) BL cases. Array-based CGH analysis identified abnormalities that are shared between adult and pediatric DLBCL (+12q15, +19q13, -6q), and abnormalities unique to the pediatric cases (-4p14, -19q13.32, +16p11.2), suggesting distinct pathogenetic mechanisms relative to age. Elucidation of the underlying target genes may provide insight into factors that modulate outcome and could provide potential novel therapeutic targets with less toxicity for pediatric patients with B-cell non-Hodgkin lymphoma.
- Published
- 2012
- Full Text
- View/download PDF
29. Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.
- Author
-
Jacobsohn DA, Arora M, Klein JP, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Bolwell BJ, Antin JH, Boyiadzis M, Cahn JY, Cairo MS, Herzig RH, Isola LM, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman SR, Weisdorf DJ, Wingard JR, Horowitz MM, and Pavletic SZ
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Chronic Disease, Female, Graft vs Host Disease mortality, Humans, Infant, Infant, Newborn, Male, Retrospective Studies, Risk Factors, Survival Analysis, Young Adult, Fetal Blood transplantation, Graft vs Host Disease epidemiology, Leukemia surgery, Myelodysplastic Syndromes surgery
- Abstract
There is a paucity of information regarding the factors that affect nonrelapse mortality (NRM) and overall survival among children that develop chronic graft-versus-host disease (cGVHD). We performed multivariate analyses using data from the Center for International Blood and Marrow Transplant Research to identify risk factors for NRM and survival in 1117 pediatric subjects with leukemia or myelodysplastic syndrome, transplanted from related donors, unrelated donors (URD), or unrelated cord blood between 1995 and 2004. We identified 4 variables associated with higher NRM: HLA partially matched or mismatched URD, peripheral blood cell graft, Karnofsky/Lansky score < 80 at cGVHD diagnosis, and platelets < 100 × 10(9)/L at cGVHD diagnosis. Factors associated with significantly worse survival were: age > 10 years, transplantation from HLA partially matched or mismatched URD, advanced disease at transplantation, Karnofsky/Lansky < 80; and platelets < 100 × 10(9)/L. Cumulative incidence of discontinuation of systemic immune suppression at 1, 3, and 5 years after diagnosis of cGVHD were 22% (20%-25%), 34% (31%-37%), and 37% (34%-40%), respectively. This is the largest study elucidating variables affecting outcome after diagnosis of cGVHD in pediatric allograft recipients. These variables may be useful for risk stratification, development of future clinical trials, and family counseling in children with cGVHD.
- Published
- 2011
- Full Text
- View/download PDF
30. Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function.
- Author
-
Satwani P, van de Ven C, Ayello J, Cairo D, Simpson LL, Baxi L, and Cairo MS
- Subjects
- Apoptosis drug effects, Cell Line, Cell Survival drug effects, Flow Cytometry, Humans, Fetal Blood cytology, Interleukin-15 pharmacology, Interleukin-2 pharmacology, Killer Cells, Natural cytology, Killer Cells, Natural drug effects, Muromonab-CD3 pharmacology, fms-Like Tyrosine Kinase 3 pharmacology
- Abstract
Background Aims: Interleukin (IL)-15 and fms-like tyrosine kinase-3 (FLT-3) are crucial factors for the development of human and murine natural killer (NK) cells. Previously, we have demonstrated significant ex vivo expansion and activation of unrelated cord blood (UCB) NK cells with an antibody/cytokine cocktail consisting of anti-CD3 + IL-2 + IL-12 + IL-7 and anti-CD3 + IL-2 + IL-12 + IL-18., Methods: In the current experiments, we investigated the effects of short-term culture with anti-CD3 + IL-2 + FLT-3 + IL-15 on cord blood (CB) NK cell and NK-cell subset expansion and function. CB mononuclear cells were cultured for 48 h in AIM-V media or AIM-V + IL-2 (5 ng/mL) + anti-CD3 (50 ng/mL) + FLT-3 (50 ng/mL) ± escalating doses of IL-15 (1, 10 or 100 ng/mL). Flow cytometric analysis was performed using various fluorescent-conjugated monoclonal antibodies. In vitro cytotoxicity was determined with a standard europium assay against K562 and Daudi cells., Results: There was a 4.8-fold significant increase in NK-cell population (CD3(-)/16(+)/56(+); P < 0.03), 21-fold significant increase in CD3(-)/56(+)/158a(+) (KIR2DL1/S1; P < 0.002), 46-fold significant increase in CD3(-)/56(+)/158b(+) (KIR2DL1/S2; P < 0.002) and 11.5-fold significant increase in CD3(-)/56(+)/NKB1(+) (KIR3DL1; P < 0.01). We also noted a significant increase in both NK and lymphokine-activated killer (LAK) cytotoxicity with IL-2 + anti-CD3 + FLT-3 + IL-15 (100 ng/mL) compared with IL-2 + anti-CD3 + FLT-3 and media alone against K562 (P < 0.01) and Daudi (P < 0.001), respectively., Conclusions: We have demonstrated a significant increase in UCB NK cells and NK cells expressing a variety of killer immunoglobulin-like receptor (KIR) receptors after short-term culture with anti-CD3, IL-2, FLT-3 and IL-15. Furthermore, there was a significant increase in in vitro NK/LAK cell cytotoxicity.
- Published
- 2011
- Full Text
- View/download PDF
31. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.
- Author
-
Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola L, Jacobsohn DA, Jagasia M, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman S, Wingard JR, Horowitz MM, and Pavletic SZ
- Subjects
- Adolescent, Adult, Aged, Biomedical Research statistics & numerical data, Blood Transfusion statistics & numerical data, Child, Child, Preschool, Chronic Disease, Cohort Studies, Female, Graft vs Host Disease epidemiology, Graft vs Host Disease mortality, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation mortality, Hematopoietic Stem Cell Transplantation statistics & numerical data, Humans, Infant, International Agencies, Male, Middle Aged, Multicenter Studies as Topic, Registries statistics & numerical data, Research Design, Risk Factors, Severity of Illness Index, Survival Analysis, Young Adult, Graft vs Host Disease etiology
- Abstract
Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD), but there is considerable variability in the reported factors. Therefore, we evaluated patient, transplantation, and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables were identified as being significant in multivariate analysis of overall survival and nonrelapse mortality (NRM): age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count. These 10 variables were used to build a cGVHD risk score, and 6 risk groups (RGs) were identified. The 5-year NRM was 5% (1%-9%) in RG1, 20% (19%-23%) in RG2, 33% (29%-37%) in RG3, 43% (40%-46%) in RG4, 63% (53%-74%) in RG5, and 72% (59%-85%) in RG6. The 5-year overall survival was highest at 91% (95% confidence interval [CI]:85%-97%) in RG1, followed by 67% (65%-69%) in RG2, 51% (46%-55%) in RG3, 40% (37%-43%) in RG4, 21% (12%-30%) in RG5, and 4% (0%-9%) in RG6 (all P < .01). This analysis demonstrates the usefulness of data from a large registry to develop risk-score categories for major transplantation outcomes. Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability.
- Published
- 2011
- Full Text
- View/download PDF
32. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.
- Author
-
Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, and Straus SE
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, B-Lymphocytes pathology, Child, Child, Preschool, Chronic Disease, Combined Modality Therapy, Cytokines metabolism, DNA, Viral genetics, Epstein-Barr Virus Infections immunology, Epstein-Barr Virus Infections virology, Female, Herpesvirus 4, Human immunology, Humans, Japan, Killer Cells, Natural pathology, Lymphoproliferative Disorders immunology, Lymphoproliferative Disorders virology, Male, Middle Aged, Polymerase Chain Reaction, RNA, Viral genetics, Survival Rate, T-Lymphocytes pathology, Treatment Outcome, United States, Young Adult, Epstein-Barr Virus Infections therapy, Hematopoietic Stem Cell Transplantation, Herpesvirus 4, Human genetics, Lymphoproliferative Disorders therapy
- Abstract
Chronic active EBV disease (CAEBV) is a lymphoproliferative disorder characterized by markedly elevated levels of antibody to EBV or EBV DNA in the blood and EBV RNA or protein in lymphocytes in tissues. We present our experience with CAEBV during the last 28 years, including the first 8 cases treated with hematopoietic stem cell transplantation in the United States. Most cases of CAEBV have been reported from Japan. Unlike CAEBV in Japan, where EBV is nearly always found in T or natural killer (NK) cells in tissues, EBV was usually detected in B cells in tissues from our patients. Most patients presented with lymphadenopathy and splenomegaly; fever, hepatitis, and pancytopenia were common. Most patients died of infection or progressive lymphoproliferation. Unlike cases reported from Japan, our patients often showed a progressive loss of B cells and hypogammaglobulinemia. Although patients with CAEBV from Japan have normal or increased numbers of NK cells, many of our patients had reduced NK-cell numbers. Although immunosuppressive agents, rituximab, autologous cytotoxic T cells, or cytotoxic chemotherapy often resulted in short-term remissions, they were not curative. Hematopoietic stem cell transplantation was often curative for CAEBV, even in patients with active lymphoproliferative disease that was unresponsive to chemotherapy. These studies are registered at http://www.clinicaltrials.gov as NCT00032513 for CAEBV, NCT00062868 and NCT00058812 for EBV-specific T-cell studies, and NCT00578539 for the hematopoietic stem cell transplantation protocol.
- Published
- 2011
- Full Text
- View/download PDF
33. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.
- Author
-
Shaw PJ, Kan F, Woo Ahn K, Spellman SR, Aljurf M, Ayas M, Burke M, Cairo MS, Chen AR, Davies SM, Frangoul H, Gajewski J, Gale RP, Godder K, Hale GA, Heemskerk MB, Horan J, Kamani N, Kasow KA, Chan KW, Lee SJ, Leung WH, Lewis VA, Miklos D, Oudshoorn M, Petersdorf EW, Ringdén O, Sanders J, Schultz KR, Seber A, Setterholm M, Wall DA, Yu L, and Pulsipher MA
- Subjects
- Adolescent, Child, Child, Preschool, Disease-Free Survival, Female, Graft vs Host Disease etiology, HLA Antigens, Histocompatibility Testing, Humans, Infant, Leukemia immunology, Leukemia mortality, Male, Multivariate Analysis, Myelodysplastic Syndromes immunology, Myelodysplastic Syndromes mortality, Siblings, Survival Analysis, Treatment Outcome, Bone Marrow Transplantation adverse effects, Bone Marrow Transplantation immunology, Bone Marrow Transplantation mortality, Leukemia therapy, Living Donors, Myelodysplastic Syndromes therapy
- Abstract
Although some trials have allowed matched or single human leukocyte antigen (HLA)-mismatched related donors (mmRDs) along with HLA-matched sibling donors (MSDs) for pediatric bone marrow transplantation in early-stage hematologic malignancies, whether mmRD grafts lead to similar outcomes is not known. We compared patients < 18 years old reported to the Center for International Blood and Marrow Transplant Research with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and myelodysplastic syndrome undergoing allogeneic T-replete, myeloablative bone marrow transplantation between 1993 and 2006. In total, patients receiving bone marrow from 1208 MSDs, 266 8/8 allelic-matched unrelated donors (URDs), and 151 0-1 HLA-antigen mmRDs were studied. Multivariate analysis showed that recipients of MSD transplants had less transplantation-related mortality, acute graft-versus-host disease (GVHD), and chronic GVHD, along with better disease-free and overall survival than the URD and mmRD groups. No differences were observed in transplant-related mortality, acute and chronic GVHD, relapse, disease-free survival, or overall survival between the mmRD and URD groups. These data show that mmRD and 8/8 URD outcomes are similar, whereas MSD outcomes are superior to the other 2 sources. Whether allele level typing could identify mmRD recipients with better outcomes will not be known unless centers alter practice and type mmRD at the allele level.
- Published
- 2010
- Full Text
- View/download PDF
34. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.
- Author
-
Litzow MR, Tarima S, Pérez WS, Bolwell BJ, Cairo MS, Camitta BM, Cutler CS, de Lima M, Dipersio JF, Gale RP, Keating A, Lazarus HM, Luger S, Marks DI, Maziarz RT, McCarthy PL, Pasquini MC, Phillips GL, Rizzo JD, Sierra J, Tallman MS, and Weisdorf DJ
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Disease-Free Survival, Female, Graft vs Host Disease etiology, Humans, Leukemia, Myeloid, Acute etiology, Male, Middle Aged, Myelodysplastic Syndromes etiology, Neoplasms, Second Primary etiology, Prognosis, Recurrence, Risk Factors, Survival Analysis, Transplantation, Homologous, Young Adult, Hematopoietic Stem Cell Transplantation adverse effects, Leukemia, Myeloid, Acute therapy, Myelodysplastic Syndromes therapy, Neoplasms, Second Primary therapy
- Abstract
Therapy-related myelodysplastic syndromes (t-MDSs) and acute myeloid leukemia (t-AML) have a poor prognosis with conventional therapy. Encouraging results are reported after allogeneic transplantation. We analyzed outcomes in 868 persons with t-AML (n = 545) or t-MDS (n = 323) receiving allogeneic transplants from 1990 to 2004. A myeloablative regimen was used for conditioning in 77%. Treatment-related mortality (TRM) and relapse were 41% (95% confidence interval [CI], 38-44) and 27% (24-30) at 1 year and 48% (44-51) and 31% (28-34) at 5 years, respectively. Disease-free (DFS) and overall survival (OS) were 32% (95% CI, 29-36) and 37% (34-41) at 1 year and 21% (18-24) and 22% (19-26) at 5 years, respectively. In multivariate analysis, 4 risk factors had adverse impacts on DFS and OS: (1) age older than 35 years; (2) poor-risk cytogenetics; (3) t-AML not in remission or advanced t-MDS; and (4) donor other than an HLA-identical sibling or a partially or well-matched unrelated donor. Five-year survival for subjects with none, 1, 2, 3, or 4 of these risk factors was 50% (95% CI, 38-61), 26% (20-31), 21% (16-26), 10% (5-15), and 4% (0-16), respectively (P < .001). These data permit a more precise prediction of outcome and identify subjects most likely to benefit from allogeneic transplantation.
- Published
- 2010
- Full Text
- View/download PDF
35. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.
- Author
-
Ringdén O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, and Arora M
- Subjects
- Adolescent, Adult, Female, Follow-Up Studies, Graft vs Host Disease epidemiology, Humans, Incidence, Leukemia immunology, Leukemia mortality, Leukemia therapy, Male, Middle Aged, Young Adult, Graft vs Leukemia Effect immunology, HLA Antigens immunology, Hematopoietic Stem Cell Transplantation mortality, Histocompatibility Testing, Siblings, Tissue Donors
- Abstract
Do some patients benefit from an unrelated donor (URD) transplant because of a stronger graft-versus-leukemia (GVL) effect? We analyzed 4099 patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) undergoing a myeloablative allogeneic hematopoietic cell transplantation (HCT) from an URD (8/8 human leukocyte antigen [HLA]-matched, n=941) or HLA-identical sibling donor (n=3158) between 1995 and 2004 reported to the CIBMTR. In the Cox regression model, acute and chronic GVHD were added as time-dependent variables. In multivariate analysis, URD transplant recipients had a higher risk for transplantation-related mortality (TRM; relative risk [RR], 2.76; P< .001) and relapse (RR, 1.50; P< .002) in patients with AML, but not ALL or CML. Chronic GVHD was associated with a lower relapse risk in all diagnoses. Leukemia-free survival (LFS) was decreased in patients with AML without acute GVHD receiving a URD transplant (RR, 2.02; P< .001) but was comparable to those receiving HLA-identical sibling transplants in patients with ALL and CML. In patients without GVHD, multivariate analysis showed similar risk of relapse but decreased LFS for URD transplants for all 3 diagnoses. In conclusion, risk of relapse was the same (ALL, CML) or worse (AML) in URD transplant recipients compared with HLA-identical sibling transplant recipients, suggesting a similar GVL effect.
- Published
- 2009
- Full Text
- View/download PDF
36. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.
- Author
-
Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, and Patte C
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Neoplasms drug therapy, Bone Marrow Neoplasms mortality, Burkitt Lymphoma mortality, Central Nervous System Neoplasms mortality, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Infant, Lymphoma, B-Cell mortality, Male, Risk Factors, Survival Rate, Treatment Failure, Burkitt Lymphoma drug therapy, Central Nervous System Neoplasms drug therapy, Lymphoma, B-Cell drug therapy
- Abstract
The prognosis for higher risk childhood B-cell non-Hodgkin lymphoma has improved over the past 20 years but the optimal intensity of treatment has yet to be determined. Children 21 years old or younger with newly diagnosed B-cell non-Hodgkin lymphoma/B-cell acute lymphoblastic leukemia (B-NHL/B-ALL) with higher risk factors (bone marrow [BM] with or without CNS involvement) were randomized to standard intensity French-American-British/Lymphoma Malignancy B (FAB/LMB) therapy or reduced intensity (reduced cytarabine plus etoposide and deletion of 3 maintenance courses M2, M3, M4). All patients with CNS disease had additional high-dose methotrexate (8 g/m2) plus extra intrathecal therapy. Fifty-one percent had BM involvement, 20% had CNS involvement, and 29% had BM and CNS involvement. One hundred ninety patients were randomized. The probabilities of 4-year event-free survival (EFS) and survival (S) were 79% +/- 2.7% and 82% +/- 2.6%, respectively. In patients in remission after 3 cycles who were randomized to standard versus reduced-intensity therapy, the 4-year EFS after randomization was 90% +/- 3.1% versus 80% +/- 4.2% (one-sided P = .064) and S was 93% +/- 2.7% versus 83% +/- 4.0% (one-sided P = .032). Patients with either combined BM/CNS disease at diagnosis or poor response to cyclophosphamide, Oncovin [vincristine], prednisone (COP) reduction therapy had a significantly inferior EFS and S (P < .001). Standard-intensity FAB/LMB therapy is recommended for children with high-risk B-NHL (B-ALL with or without CNS involvement).
- Published
- 2007
- Full Text
- View/download PDF
37. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
- Author
-
Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, and Cairo MS
- Subjects
- Adolescent, Adult, Burkitt Lymphoma drug therapy, Child, Child, Preschool, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Female, Humans, Lymphoma, B-Cell mortality, Lymphoma, Large B-Cell, Diffuse drug therapy, Male, Methotrexate administration & dosage, Prednisone administration & dosage, Remission Induction, Risk Factors, Survival Rate, Time Factors, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Lymphoma, B-Cell drug therapy
- Abstract
A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for intermediate-risk group B defined as "non-resected" stage II/I and CNS-negative advanced-stage IIV/IV (70% of cases). We performed the FAB/LMB96 trial to assess the possibility of reducing treatment in children/adolescents with intermediate-risk B-NHL without jeopardizing survival. "Early responding" patients (tumor response > 20% at day 7) were randomized in a factorial design between 4 arms, 2 receiving half-dose of cyclophosphamide in the second induction course with cyclophosphamide, Oncovin (vincristine), prednisone, Adriamycin (doxorubicin), methotrexate (COPADM) and 2 not receiving the maintenance course M1. A total of 657 patients were randomized (May 1996 to June 2001) and 637 were analyzed. The analysis showed no significant effect of any of the treatment reductions on EFS and survival. The 4-year EFS was 93.4% and 90.9% in the groups with full-dose and half-dose of cyclophosphamide (RR = 1.3, P = .40) and 91.9% and 92.5% in the groups with and without M1 (RR = 1.01, P = .98). There was no interaction between the 2 treatment reductions or between each treatment reduction and LDH level or histologic subtypes (Burkitt/Burkitt-like or large B-cell). Children/adolescents with intermediate-risk B-NHL who have an early response and achieve a complete remission after the first consolidation course can be cured with a 4-course treatment with a total dose of only 3.3 g/m2 cyclophosphamide and 120 mg/m2 doxorubicin.
- Published
- 2007
- Full Text
- View/download PDF
38. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.
- Author
-
Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, and van Besien K
- Subjects
- Adolescent, Adult, Aged, Disease Progression, Female, Hematopoietic Stem Cell Transplantation mortality, Humans, Lymphoma mortality, Male, Middle Aged, Multivariate Analysis, Prognosis, Recurrence, Registries, Retrospective Studies, Survival Analysis, Transplantation Conditioning methods, Transplantation, Autologous, Transplantation, Homologous, Treatment Outcome, Hematopoietic Stem Cell Transplantation methods, Lymphoma therapy, Myeloablative Agonists therapeutic use
- Abstract
Myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasingly used in patients with lymphoma who experience disease relapse after autologous hematopoietic stem cell transplantation (auto-HSCT) because the allograft is tumor free and may induce a graft-versus-tumor effect. We analyzed 114 patients treated with this approach from 1990 to 1999 to assess disease progression, progression-free survival (PFS), and overall survival (OS). Cumulative incidence of disease progression at 3 years was 52%, whereas treatment-related mortality was 22%, lower than previously reported. Three-year probabilities of OS and PFS were 33% and 25%, respectively. With prolonged follow-up, however, nearly all patients experienced disease progression, and 5-year probabilities were 24% and 5%, respectively. Complete remission at the time of allo-HSCT and use of total body irradiation (TBI) in patients with non-Hodgkin lymphoma (NHL) were associated with lower rates of disease progression and higher rates of OS. In summary, allo-HSCT is feasible for patients with lymphoma who have relapses after auto-HSCT and can result in prolonged survival for some, but it is usually not curative. Most likely to benefit are patients who have HLA-matched sibling donors, are in remission, and have good performance status.
- Published
- 2004
- Full Text
- View/download PDF
39. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
- Author
-
Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, and Horowitz MM
- Subjects
- Adolescent, Adult, Female, Humans, Male, Markov Chains, Middle Aged, Risk Factors, Survival Analysis, Treatment Outcome, Bone Marrow Transplantation mortality, Decision Support Techniques, Myelodysplastic Syndromes mortality, Myelodysplastic Syndromes therapy
- Abstract
Bone marrow transplantation (BMT) can cure myelodysplastic syndrome (MDS), although transplantation carries significant risks of morbidity and mortality. Because the optimal timing of HLA-matched BMT for MDS is unknown, we constructed a Markov model to examine 3 transplantation strategies for newly diagnosed MDS: transplantation at diagnosis, transplantation at leukemic progression, and transplantation at an interval from diagnosis but prior to leukemic progression. Analyses using individual patient risk-assessment data from transplantation and nontransplantation registries were performed for all 4 International Prognostic Scoring System (IPSS) risk groups with adjustments for quality of life (QoL). For low and intermediate-1 IPSS groups, delayed transplantation maximized overall survival. Transplantation prior to leukemic transformation was associated with a greater number of life years than transplantation at the time of leukemic progression. In a cohort of patients under the age of 40 years, an even more marked survival advantage for delayed transplantation was noted. For intermediate-2 and high IPSS groups, transplantation at diagnosis maximized overall survival. No changes in the optimal transplantation strategies were noted when QoL adjustments were incorporated. For low- and intermediate-1-risk MDS, delayed BMT is associated with maximal life expectancy, whereas immediate transplantation for intermediate-2- and high-risk disease is associated with maximal life expectancy.
- Published
- 2004
- Full Text
- View/download PDF
40. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.
- Author
-
Levine JE, Harris RE, Loberiza FR Jr, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, and Zhang MJ
- Subjects
- Adolescent, Adult, Bone Marrow Transplantation mortality, Bone Marrow Transplantation statistics & numerical data, Child, Child, Preschool, Data Collection, Disease-Free Survival, Female, Hematopoietic Stem Cell Transplantation methods, Hematopoietic Stem Cell Transplantation mortality, Hematopoietic Stem Cell Transplantation statistics & numerical data, Humans, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Recurrence, Retrospective Studies, Survival Rate, Transplantation, Autologous mortality, Transplantation, Autologous statistics & numerical data, Transplantation, Homologous mortality, Transplantation, Homologous statistics & numerical data, Transplantation, Isogeneic, Treatment Outcome, Bone Marrow Transplantation methods, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
- Abstract
Lymphoblastic lymphoma (LBL) is a rare, clinically aggressive neoplasm of the young that frequently involves the bone marrow (BM) and/or central nervous system. Because LBL is similar to acute lymphoblastic leukemia, some centers prefer allogeneic hematopoietic stem cell (SC) transplantation to autologous SC transplantation. We retrospectively analyzed outcomes for patients who underwent autologous (auto, n = 128) or HLA-identical sibling (allo, n = 76) SC transplantations from 1989 to 1998 and were reported to International Bone Marrow Transplant Registry (IBMTR) or Autologous Blood and Marrow Transplant Registry (ABMTR). Allo stem cell transplant (SCT) recipients had higher treatment-related mortality (TRM) at 6 months (18% versus 3%, P =.002), and this disadvantage persisted at 1 and 5 years. Early relapse rates after alloSC transplantation and autoSC transplantation were similar, but significantly lower relapse rates were observed in alloSCT recipients at 1 and 5 years (32% versus 46%, P =.05; and 34% versus 56%, P =.004, respectively). No differences were noted in lymphoma-free survival rates between alloSC transplantations and autoSC transplantations (5-year rates 36% versus 39%, P =.82). AutoSCT recipients had higher overall survival at 6 months (75% versus 59%, P =.01), but survival did not significantly differ between the 2 groups at 1 and 5 years (60% versus 49%, P =.09; 44% versus 39%, P =.47, respectively). Multivariate analyses to account for confounding factors confirmed these results. Independent of SCT type, BM involvement at the time of transplantation and disease status more advanced than first complete remission were associated with inferior outcomes. In summary, alloSC transplantation for LBL is associated with fewer relapses than with autoSC transplantation, but higher TRM offsets any potential survival benefit.
- Published
- 2003
- Full Text
- View/download PDF
41. B large-cell lymphoma in children and adolescents.
- Author
-
Raetz E, Perkins S, Davenport V, and Cairo MS
- Subjects
- Adolescent, Antineoplastic Agents therapeutic use, Child, Clinical Trials as Topic, Humans, Lymphoma, B-Cell mortality, Lymphoma, Large B-Cell, Diffuse mortality, Prognosis, Survival Rate, Treatment Outcome, Lymphoma, B-Cell drug therapy, Lymphoma, Large B-Cell, Diffuse drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
The prognosis of advanced B-large cell lymphoma (B-LCL) in children and adolescents has improved dramatically over the past 25 years (30-40% to 80-90% 5-year event-free survival (EFS)). Using strategies of treatment allocation based upon risk of disease recurrence, the total duration of therapy has been successfully reduced for many patients, and the prior requirement for radiotherapy largely eliminated. Instead of 18-30 months of combined chemotherapy and radiotherapy, current therapy has been decreased to between 6 weeks and 6 months of intensive chemotherapy. Multiagent chemotherapeutic approaches have been optimized with the use of moderate to high-dose methotrexate and further intensification with cytarabine and etoposide. The prognosis for children and adolescents who progress or relapse on current therapy for B-LCL, however, has decreased over the past 25 years with approximately 80% or 90% surviving at the present time. B-LCL in children and adolescents uniformly expresses CD20 and CD22 surface antigens. New treatment strategies employing targeted monoclonal antibody therapy combined with chemotherapy and targeted conjugated monoclonal antibody therapy conjugated with radioactive compounds and toxins are currently being investigated. Future studies utilizing immunophenotyping, cytogenetics, molecular genetics, and gene expression profiles (microarray) are required to better define the biological heterogeneity and differential clinical outcomes among children and adolescents with B-LCL.
- Published
- 2003
- Full Text
- View/download PDF
42. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.
- Author
-
van Rood JJ, Loberiza FR Jr, Zhang MJ, Oudshoorn M, Claas F, Cairo MS, Champlin RE, Gale RP, Ringdén O, Hows JM, and Horowitz MH
- Subjects
- Adolescent, Adult, Bone Marrow Transplantation adverse effects, Bone Marrow Transplantation mortality, Child, Child, Preschool, Female, Graft Survival, Graft vs Host Disease etiology, Graft vs Host Disease mortality, Haplotypes immunology, Histocompatibility immunology, Humans, Incidence, Infant, Leukemia complications, Leukemia mortality, Leukemia therapy, Male, Middle Aged, Nuclear Family, Pregnancy, Transplantation, Homologous adverse effects, Transplantation, Homologous immunology, Transplantation, Homologous mortality, Bone Marrow Transplantation immunology, Graft vs Host Disease immunology, HLA Antigens immunology, Immune Tolerance, Maternal-Fetal Exchange immunology
- Abstract
In haploidentical transplantation, the mismatched haplotype of the donor can originate from either of the parents. We refer to such mismatched haplotypes as noninherited maternal antigens (NIMA haplotype) or noninherited paternal antigens (NIPA haplotype). To determine whether exposure to maternal HLA antigens benefits patients undergoing bone marrow transplantation, we analyzed graft failure and graft-versus-host disease (GVHD) after transplantations from parental or haploidentical sibling donors. We studied 269 patients receiving 1 or 2 HLA-A, -B, -DR antigen-mismatched sibling or parental non-T-cell-depleted bone marrow transplants for acute myelogenous leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia between 1985 and 1997 that were reported to the International Bone Marrow Transplant Registry. Included were 121 (45%) NIMA-mismatched and 148 (55%) NIPA-mismatched transplantations. Sixty-three (52%) of the NIMA-mismatched transplants and 69 (47%) of the NIPA-mismatched transplants were from haploidentical sibling donors. Sibling transplantations mismatched for NIMA had similar rates of graft failure but lower rates of acute GVHD (P <.02) than NIPA-mismatched sibling transplantations. In the first 4 months after transplantation, mother-to-child transplantations involved significantly less chronic GVHD than father-to-child transplantations (P <.02). Treatment-related mortality (TRM) was significantly higher after parental transplantations (P =.009 for mother; P =.03 for father) than after haploidentical sibling transplantations mismatched for the NIMA. Non-T-cell-depleted bone marrow transplants donated by haploidentical siblings to recipients mismatched for NIPA and transplants donated by parents caused more acute and chronic GVHD and TRM than transplants donated by haploidentical siblings mismatched for NIMA.
- Published
- 2002
- Full Text
- View/download PDF
43. Liposomal amphotericin B (AmBisome) compared with amphotericin B +/- FMLP induces significantly less in vitro neutrophil aggregation with granulocyte-colony-stimulating factor/dexamethasone-mobilized allogeneic donor neutrophils.
- Author
-
Sulis ML, Van de Ven C, Henderson T, Anderson L, and Cairo MS
- Subjects
- Amphotericin B adverse effects, Antifungal Agents adverse effects, Blood Donors, Cell Aggregation drug effects, Dexamethasone pharmacology, Glucocorticoids pharmacology, Humans, Leukapheresis, Liposomes administration & dosage, Mycoses etiology, Mycoses therapy, N-Formylmethionine Leucyl-Phenylalanine adverse effects, Neutropenia complications, Neutropenia therapy, Amphotericin B administration & dosage, Antifungal Agents administration & dosage, Granulocyte Colony-Stimulating Factor pharmacology, Leukocyte Transfusion, N-Formylmethionine Leucyl-Phenylalanine administration & dosage, Neutrophils drug effects
- Abstract
Concomitant use of allogeneic donor granulocyte transfusions and amphotericin B in febrile neutropenic recipients may be limited by the increased incidence of respiratory distress. In vitro effects of amphotericin B and AmBisome were compared on polymorphonuclear leukocyte (PMN) aggregation from PMNs isolated from granulocyte-colony-stimulating factor (G-CSF)/dexamethasone-mobilized allogeneic donors. Six allogeneic donors were mobilized with G-CSF (600 microg subcutaneously) and dexamethasone (8 mg orally) 12 hours before leukopheresis. AmBisome was associated with significantly less PMN aggregation (100 microM [microg/mL]) (0.33% +/- 0.33% vs 54.33% +/- 5.82%; P <.001) than amphotericin B. Furthermore, with the addition of the PMN agonist, FMLP, AmBisome was also associated with significantly less aggregation (100 microM [microg/mL]) (18.67% +/- 1.45% vs 54.67% +/- 2.4%; P <.001). In summary, these studies demonstrate that liposomal amphotericin is associated with significantly less in vitro PMN aggregation than amphotericin B and could possibly be administered concomitantly with mobilized allogeneic PMN infusions.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.